# MEDICARE PRESCRIPTION DRUG BENEFIT

# Solicitation for Applications from Medicare Advantage Prescription Drug Plans (MA-PD) Sponsors

**January 21, 2005** (as revised March 9, 2005)

PUBLIC REPORTING BURDEN: According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0936. The time required to complete this information collection is estimated to average 42 hours per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have any comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, N2-14-26, Baltimore, Maryland 21244-1850.

#### **Table of Contents**

#### 1. GENERAL INFORMATION

- 1.1 Purpose of Solicitation
- 1.2 Background
- 1.3 Objectives and Structure
- 1.4 Part D Schedule
- 1.5 Summary of MA-PD Sponsor Role and Responsibilities
- 1.6 Summary of CMS Role and Responsibilities

#### 2. INSTRUCTIONS

- 2.1 Overview
- 2.2 Pre-Application Conferences
- 2.3 Other Technical Support
- 2.4 Notice of Intent to Apply for New MA Organizations Only
- 2.5 Instructions and Format of Qualifications
- 2.6 Submission Software Training
- 2.7 System and Data Testing with CMS
- 2.8 Summary Instruction and Format for Part D Bids
  - 2.8.1 Format of Part D Bids
  - 2.8.2 CMS Review of Part D Bids
  - 2.8.3 Overview of Part D Bid Negotiation
- 2.9 Standard Contract with MA-PD Sponsors
- 2.10 Additional Information Available
- 2.11 Protection of Confidential Information
- 2.12 Waivers

#### 3. APPLICATION

- 3.1 Applicant Experience, Contracts, Licensure and Financial Stability
  - 3.1.1 Management and Operations
  - 3.1.2 Experience and Capabilities
  - 3.1.3 Business Integrity
- 3.2 Benefit Design
  - 3.2.1 Pharmacy and Therapeutics (P&T) Committee
  - 3.2.2 Utilization Management Standards
  - 3.2.3 Quality Assurance and Patient Safety

- 3.2.4 Medication Therapy Management
- 3.2.5 Electronic Prescription Program
- 3.3 Service Area/Regions
- 3.4 Pharmacy Access
  - 3.4.1 Retail Pharmacy
  - 3.4.2 Out-of-Network Pharmacy
  - 3.4.3 Mail Order Pharmacy
  - 3.4.4 Home Infusion Pharmacy
  - 3.4.5 Long Term Care (LTC) Pharmacy
  - 3.4.6 Indian Health Service, Indian Tribe and Tribal Organization, and Urban Indian Organization I/T/U Pharmacy
- 3.5 Exceptions, Appeals and Grievances
- 3.6 Coordination of Benefits
- 3.7 Tracking Out-of-Pocket Costs (TrOOP)
- 3.8 Marketing/Beneficiary Communications
- 3.9 Provider Communication
- 3.10 Compliance Plan
- 3.11 Reporting Requirements
- 3.12 Data Exchange between MA-PD and CMS

Payment

- 3.13 Claims Processing
- 3.14 Privacy
- 3.15 Security and Record Retention

#### 4. CERTIFICATION

## 5. APPENDICES

Appendix I	Notice of Intent to Apply Form
Appendix II	CMS Connectivity Request Form
Appendix III	Instructions for Accessing CMS Systems
Appendix IV	Banking Information Form
Appendix V	Summary of PDP Application Requirements Waived for Medicare Advantage Prescription Drug (MA-PD) Applicants
Appendix VI	Pharmacy Access Standards
Appendix VII	Certification of Monthly Enrollment and Payment Data Relating to CMS

Appendix VIII Certification that Subcontractors Meet the Requirements of Section 3.1.1D

Appendix IX Citations of Section 3.1.1D Requirements on Subcontracts submitted as attachments to Section 3.1.1D

# Appendix X Citations for Pharmacy Access Contracts

#### 1. GENERAL INFORMATION

## 1.1 Purpose of Solicitation

The Centers for Medicare & Medicaid Services is seeking applications from Medicare Advantage organizations to enter into a contract to offer qualified prescription drug coverage as described in the Medicare Prescription Drug Benefit Plan Final Rule as published in the Federal Register. Please submit your applications according to the process described in Section 2.0. If you are a New Medicare Advantage Applicant, you must submit a notice of intent to apply as describe in Section 2.4. If you are a transitioning Medicare Advantage Applicant, you are not required to complete the Notice of Intent to Apply.

#### 1.2 Background

The Medicare Prescription Drug Benefit program was established by section 101 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) and is codified in section 1860D-1 through 1860D-41 of the Social Security Act (the Act). Section 101 of the MMA amended Title XVIII of the Social Security Act by redesignating Part D as Part E and inserting a new Part D, which establishes the Voluntary Prescription Drug Benefit Program (hereinafter referred to as "Part D").

## 1.3 Objectives and Structure

The new Part D benefit constitutes perhaps the most significant change to the Medicare program since its inception in 1965. The addition of outpatient drugs to the Medicare program reflects Congress' recognition of the fundamental change in recent years in how medical care is delivered in the U.S. It recognizes the vital role of prescription drugs in our health care delivery system, and the need to modernize Medicare to assure their availability to Medicare beneficiaries. Effective January 1, 2006, the Part D program establishes a voluntary prescription drug benefit for individuals who are entitled to Medicare Part A or enrolled in Part B.

In general, coverage for the new prescription drug benefit will be provided predominantly through at-risk prescription drug plans (PDPs) that offer drug-only coverage, or through Medicare Advantage (MA) plans that offer integrated prescription drug and health care coverage (MA-PD plans). PDPs must offer a basic Part D drug benefit. MA-PD plans must offer either a basic benefit or broader coverage for no additional cost. Medicare cost plans and PACE organizations may, at their election, offer a Part D drug plan in the same manner as an MA-PD plan. If the MA-PD plan meets the basic requirement, the MA-PD may also offer supplemental benefits through enhanced alternative coverage for an additional premium. MA organizations approved to offer Part D benefits (hereinafter referred to as "MA-PD sponsors") must offer Part D coverage throughout their approved MA service area.

Applicants who offer either a PDP or MA-PD plan may offer national (i.e. offering a plan in every region) or regional plans. MA-PD plan applicants may also offer local plans. CMS has identified 26 MA Regions and 34 PDP Regions, not including territories, in which PDPs or regional MA-PDs may be offered. Additional information about the regions can be found at <a href="http://www.cms.hhs.gov/medicarereform/mmaregions">http://www.cms.hhs.gov/medicarereform/mmaregions</a>.

The MMA requires that each region have at least two Medicare prescription drug plans from which to choose, and at least one of those must be a PDP. In areas where the required minimum number of plan choices is not available, the MMA requires CMS to contract with Fallback Entities. Fallback Entities must satisfy the same requirements as PDPs, but will receive reimbursement for drug costs from CMS on a cost rather than a risk basis. This solicitation is only for entities seeking to operate a MA-PD Sponsor. Separate Part D solicitations are also posted on the CMS website, for entities offering MA Plans with a Part D Drug benefit at the local or regional levels, and for entities offering Cost Plans with a Part D benefit. Solicitations for PDP and MA-PD products for employer groups will be released later in 2005, as will a solicitation for Fallback Plans for potential Fallback regions, if any. A separate Part D solicitation for PACE organizations will be released later in 2005. PDP applicants or subcontractors acting as an integral part of the drug benefit management activities for the PDP may not apply to offer a Fallback Plan.

Part D Sponsors will have flexibility in terms of benefit design. This flexibility includes, but is not limited to, authority to establish a formulary that designates specific drugs that will be available within each therapeutic class of drugs, and the ability to have a cost-sharing structure other than the statutorily defined structure (subject to certain actuarial tests). (Plans would still be required to follow our formulary guidance. See Section 2.8.1 of this application). The plans also may include supplemental benefits coverage such that the total value of the coverage exceeds the value of basic prescription drug coverage.

Only specific types of MA organizations (i.e., entities offering Medicare coordinated care plans or Medicare private fee-for-service plans) may submit a Part D application in response to this solicitation. Medicare reasonable cost plans (as defined under Section 1876 of the Social Security Act), Program of All Inclusive Care for the Elderly (PACE) organizations (as defined in section 1894 of the Social Security Act), and employer groups may also offer pharmacy benefits under the MMA. Those entities must not complete this Part D qualification application. CMS will provide separate Part D participation instructions to cost plan contractors, PACE organizations, and employers.

It is important to note that MA organizations offering coordinated care plans <u>must</u> qualify to offer at least one plan that includes both Part C and Part D benefits throughout the organization's approved Part C service area. Similarly, MA organizations offering a preferred provider option (PPO) plan <u>must</u> offer Part D coverage throughout the PPO regions in which they are approved to offer a Part C plan. However, MA organizations offering private fee-for-service plans <u>may</u>, but are not required, to offer a Part D benefit. MA organizations should refer to the MA application materials for a more complete

discussion of MA sponsor requirements concerning their participation in the Part D program.

CMS payment to MA organizations for provision of Part C services to their enrollees will be calculated separately from the payment for the Part D benefit. Like PDP sponsors, MA-PD will have flexibility in terms of benefit design. This flexibility includes, but is not limited to, authority to establish a formulary that designates specific drugs that will be available within each therapeutic class of drugs, and the ability to have a cost-sharing structure other than the statutorily defined structure (subject to certain actuarial tests). The plans also may include supplemental benefits coverage such that the total value of the coverage exceeds the value of basic prescription drug coverage.

## 1.4 Part D Schedule

APPLICATION REVIEW PROCESS					
Date	Milestone				
January 19, 2005	Registration Closes for Pre-Application Conferences in Baltimore				
January 21, 2005	Posting of Part D solicitations on CMS website				
January 21, 2005	Registration Closes for Pre-Application Conferences in San Diego and New Orleans.				
January 24 – 27, 2005	Pre-Application Conference – Baltimore				
January 31 – February 1 2005	Pre-Application Conference – San Diego				
February 3 – 4, 2005	Pre-Application Conference – New Orleans				
February 18, 2005	New MA organizations:				
	Submit notice of intent to apply to CMS				
	2. Request HPMS Access (Includes User ID and Password Request)				
	3. Request CMS Connectivity				
March 23, 2005	Applications due				
May/June 2005	CMS sends Part D contract eligibility determination to Applicants, based on review of application. Applicant's bids must still be				
	negotiated (see below)				

FORMULARY BID AND CONTRACTING PROCESS				
Date	Milestone			
April 4 -5, 2005	CMS conducts Bid and Formulary Training Conference in Washington D.C.			
March 28 - April 18, 2005	Applicants submit formularies to CMS for review			
April 8, 2005	Applicants receive instructions to download Plan Benefit Package and Pricing Tool software from the Health Plan Management System (HPMS).			
May 16, 2005	CMS provides preliminary approval of formularies			
May 20, 2005	CMS begins accepting bid submissions via HPMS			
June 6, 2005	Qualified Applicants submit bids to CMS via HPMS for each of the Part D plans they propose to offer during 2006. Disapproved applicants			

	requesting a reconsideration of CMS' determination must submit their bids on this date as well.
June 6 - July 25, 2005	Modifications to bids accepted only at the discretion of CMS
Late July 2005	Training on submission of drug claims data to CMS
July 15, 2005	Any favorable redetermination, including those resulting from a hearing or Administrator review must be made for the contract in question to be effective on January 1 of the following year
Early August 2005	CMS publishes national average Part D premium
September 2, 2005	CMS completes review and approval of bid data. CMS executes Part D addenda to MA-PD PDP with MA-PD who submit an acceptable bid.

PRE-IMPLEMENTATION AND IMPLEMENTATION PROCESS				
Date	Milestone			
January 2005	Begin weekly Applicant/Sponsor technical support calls with CMS			
March 23, 2005	Submit contact information and other related information to HPMS			
March 28, 2005	CMS plans to release the formulary upload functionality			
April 2005	Marketing guidelines posted on CMS website			
April/May 2005	Reporting requirements posted on CMS website in April except data requirements for price compare will be available in May			
April 2005	Enrollment requirements posted on CMS website			
April 8, 2005	CMS plans to release the HPMS bid creation functionality, including the PBP and BPT software			
April 18, 2005	Formularies are due to CMS			
April 18, 2005	Responses to Quality Assurance and Patient Safety and Medication Therapy Management Program questions are due to CMS			
April 20, 2005	Details regarding submitting pricing and pharmacy network information to be posted on <a href="https://www.cms.hhs.gov">www.cms.hhs.gov</a> by this date			
May 20, 2005	CMS plans to release the PBP and BPT upload functionality			
May 20 – June 6, 2005	Applicants can submit bid uploads to HPMS			
Early Summer 2005	Establish Connectivity to AT&T Medicare Data Network (MDCN)			
June 7, 2005	MA-PD sponsors submit electronic test data to CMS			
July 2005	CMS releases Coordination of Benefit requirements			
Summer 2005	Submit Banking Information Form (Appendix IV)			
Summer 2005	Begin testing between Part D sponsors and CMS on information systems interfaces and data exchanges			
July 29, 2005	MA-PD sponsors submit corrected test data electronically to CMS			
August 2005	Re-evaluation of pharmacy access requirements			
September 2005	Training on Certification for Enrollment and Payment			
	Submit Certification of Monthly Enrollment and Payment Data			

	Relating to CMS Payment (Appendix VII)	
September 16, 2005	MA-PD sponsors submit actual data to CMS electronically for final	
	testing	
October 6, 2005	MA-PD sponsors submit data that will be published on	
	www.medicare.gov	
November 15, 2005	Part D initial enrollment period begins for individuals who are first	
	eligible to enroll in a Part D plan on or prior to January 31, 2006	
January 1, 2006	Medicare beneficiaries begin receiving drug benefits from Medicare	
	Part D contractors	
January 1, 2006	Auto-enrollment effective for beneficiaries who are full-benefit dual	
	eligible as of December 31, 2005.	
May 15, 2006	Initial enrollment period ends for individuals who are first eligible to	
	enroll in a Part D plan on or prior to January 31, 2006	

NOTE: CMS reserves the right to amend or cancel this solicitation at any time. CMS also reserves the right to revise the Medicare Prescription Drug Benefit program implementation schedule, including the solicitation and bidding process timelines.

## 1.5 Summary of MA-PD Sponsor Role and Responsibilities

Key aspects of each MA-PD sponsor shall include the ability to:

- Submit a formulary each year for CMS approval.
- As part of the annual bidding process MA Coordinated Care Plans (CCPs) must submit at least one MA-PD plan for CMS approval. An MA organization offering a coordinated care plan must offer at least one MA-PD plan throughout their approved MA service area. An MA private fee-for-service (MA-PFFS) contractor may, but is not required to, offer a Part D Benefit to beneficiaries within its service area.
- Enroll all eligible Medicare beneficiaries who apply and reside within the MA-PD sponsor's approved service area.
- Administer the Part D benefit, including providing coverage for drugs included in a CMS-approved formulary, administering appropriate deductibles and co-payments, managing the benefit using appropriate pharmacy benefit managerial tools, and operating effective oversight of that benefit.
- Provide access to negotiated prices on covered Part D drugs, with different strengths and doses available for those drugs, including a broad selection of generic drugs.
- Ensure that records are maintained in accordance with CMS rules and regulations and that both records and facilities are available for CMS inspection and audit.
- Disclose the information necessary for CMS to oversee the program and ensure appropriate payments.

- MA-PDs (except Medicare private fee for service plans) must feature a contracted retail pharmacy network, providing enrollees convenient access to retail pharmacies as specified in 42 CFR §423.120
- Process claims at the point of sale.
- All MA-PDs must operate quality assurance programs. MA-PDs, except Medicare Private Fee-for-Service plans meeting specific requirements, must also provide drug utilization review, and medication therapy management programs.
- Administer a coverage determinations, grievances, exceptions, and appeals process consistent with CMS requirements.
- Provide customer service to beneficiaries, including enrollment assistance, toll-free telephone customer service help, and education about the Part D benefit.
- Protect the privacy of beneficiaries and beneficiary-specific health information.
- Develop marketing materials and conduct outreach activities consistent with CMS standards for completeness, appropriateness, and understandability.
- Develop and/or maintain systems to support enrollment, provide claims-based data to CMS, accept CMS payment (including subsidies for low-income beneficiaries), track true out-of-pocket costs, coordinated benefits with secondary insurers (or primary insurers when Medicare is secondary), and support e-prescribing.
- Provide necessary data to CMS to support payment, oversight, and quality improvement activities and otherwise cooperate with CMS oversight responsibilities.

## 1.6 Summary of CMS Role and Responsibilities

## Application Approval, Part D Bid Review, and Contracting Processes

There are three distinct phases to the overall review to determine whether CMS will enter into a contract with an Applicant. The first phase is the Part D application review process. CMS will review the application submitted on or by March 23, 2005 to determine whether the Applicant meets the qualifications we have established to enter into a Part D addendum to the Applicant's Part C contract.

The second phase has two steps – the formulary review which begins April 18, 2005 and the Part D bid review which begins June 6, 2005. The formulary review entails determining that the proposed formulary (if one is used) has at least two drugs in every therapeutic category and class (unless special circumstances exist that would allow only one drug); does not substantially discourage enrollment by certain types of Part D eligible individuals; includes adequate coverage of the types of drugs most commonly needed by Part D enrollees; and includes an appropriate transition policy. CMS will contact

Applicants if any issues are identified during the review for discussion and resolution. The intent is to provide an opportunity for Applicants to make any necessary corrections prior to Part D bid submission on June 6, 2005. The second step involves the bid review and negotiations with plans to assure valuation of the proposed Part D benefits are reasonable and actuarially equivalent.

The third phase involves contracting. Applicants judged qualified to enter into a Part D addendum as a result of successfully completing phase one and two will be offered a Part D addendum to their Medicare managed care contract by CMS.

## Part D Program Oversight

CMS will develop a Medicare Prescription Drug Benefit program monitoring system to ensure that the plans deliver good value through defined benefits and are compliant with program requirements. This monitoring system will be developed in coordination with the CMS personnel responsible for oversight of the Medicare Advantage program to minimize duplication of effort. We will focus on several operational areas critical to the value of the benefit, including beneficiary access to and satisfaction with their Part D benefit and protection of the financial integrity of the program. Specific areas will include pharmacy access, adequacy and value of the benefit, benefit management, enrollment and disenrollment, marketing, program safeguard activities, customer service, confidentiality and security of enrollee information, and effectiveness of tracking true out-of-pocket expenses. The types of the reporting that CMS will require of Part D sponsors is presented in the application. Further detail on our approach to monitoring and oversight, including the exact reporting measures will be posted on the CMS website not later than April 2005. (NOTE: PDP sponsors, as covered entities under the Privacy Rule, are subject to investigation and penalties for findings of Privacy Rule violations as determined by the Department of Health and Human Services Office for Civil Rights and the Department of Justice.) We will monitor, through the analysis of data we collect from Part D sponsors, CMS contractors, and our own systems. The types of data we expect to collect from sponsors include: certain benefit data, claims data, cost data, benefit management data, marketing review information, and customer satisfaction and complaints data.

To monitor plan performance in the areas we have identified, we will: 1) conduct beneficiary satisfaction surveys and operate a complaints tracking system to monitor and manage complaints brought to our attention that are not satisfactorily resolved through MA-PD sponsors' grievance processes; and 2) conduct periodic site visits to verify MA-PD sponsor compliance with Part D program requirements. We will use information from all the specified sources to analyze the appropriateness and value of the benefit delivered, and to evaluate the opportunity for additional value and quality improvement. If any trends we identify indicate less than satisfactory performance, significant departures from the marketed Part D offering, or fraud or other violations of State or Federal laws, appropriate action will be taken ranging from request for corrective action plans to all categories of sanctions consistent with 42 CFR 423.509 and Part 423, Subpart O. We also will make referrals if appropriate to the Services Office of the Inspector

General, or to Federal and State authorities where violations of laws under the jurisdictions of these agencies are in question.

#### **Education and Outreach**

CMS is committed to educating Medicare beneficiaries about the Part D program. CMS plans to educate beneficiary and consumer groups, health care providers, States, and other interested groups about the Part D program. Among the topics to be discussed with these groups is the identification and reporting of possible fraud and/or abuse. CMS may also engage in other activities that publicize or otherwise educate beneficiaries about the program.

## Marketing Guidelines and Review

CMS is developing marketing guidelines and expects to post them on the CMS web site as a separate document from this solicitation not later than April 2005. Part D sponsors are required to adhere to these guidelines in developing their marketing materials and marketing strategy. We will retain a contractor to provide technical assistance in the development of these guidelines and review materials submitted by plans in accordance with statutory requirements. MA-PD sponsors are required to submit materials to CMS based on the marketing guidelines. Review of MA-PD plan materials will be conducted in conjunction with review of Part C marketing materials under 42 CFR §422.80 and 42 CFR §423.50. MA-PD sponsors are required to submit materials to CMS based on the Medicare Prescription Drug Program Marketing Guidelines.

#### Eligibility for the Low Income Subsidy Program

Low-income Medicare beneficiaries will receive full or partial subsidies of premiums and reductions in cost sharing under the Part D benefit. Certain groups of Medicare beneficiaries will automatically be eligible for the low-income subsidy program. These beneficiaries include full-benefit dual eligible individuals, Medicare beneficiaries who are recipients of Supplemental Security Income benefits, and participants in Medicare Savings Programs as Qualified Medicare Beneficiaries (QMBs), Specific Low-Income Medicare Beneficiaries (SLMBs), and Qualifying Individuals (QIs). Beneficiaries who are low-income and who do not fall into one of the automatic subsidy eligibility groups will apply for a low-income subsidy and have their eligibility determined by either the states in which they reside or the Social Security Administration (SSA). We will develop a database to track individuals who are automatically deemed subsidy-eligible or who are determined subsidy-eligible by states or SSA, and communicate the names and eligibility category of those individuals to plan sponsors as part of the enrollment files from the enrollment processing system described below.

## General Enrollment Processing

CMS has developed a system to review an individual's eligibility to enroll in a Part D plan. Beneficiaries enrolled in an MA –PD plan must obtain qualified prescription drug coverage through that plan (42 CFR §423.30 (b)). MA plan enrollees (including those enrolled in MA plans that do not include Part D coverage) are not eligible to enroll in a PDP plan unless they are enrolled in a PFFS plan that does not provide qualified prescription drug coverage, or they are enrolled in a MSA plan (42 CFR §423.30 (b)).

CMS will track low-income subsidy status and auto-enrollments of full-benefit dual eligible beneficiaries into Part D plans. Finally, CMS will track dis-enrollments from Part D plans and will deny new enrollments during any given year unless the enrollment occurs during an allowable enrollment period.

## Payment to PDPs

CMS will provide payment to MA-PD sponsors in the form of advance monthly payments (consisting of the MA-PD plan's Part D standardized bid, risk adjusted for health status, minus the beneficiary monthly premium), estimated reinsurance subsidies, and estimated low-income subsidies. After the end of the payment year, CMS will reconcile the correct amounts of low-income subsidies and reinsurance amounts against the amount paid as a part of the prospective monthly payments. Risk sharing amounts (if applicable) will be determined after all other reconciliations have been completed. For a more complete description refer to *Prescription Drug Event Data* at www.cms.hhs.gov/pdps/PrescriptionDrugEventDataPaper.pdf.

#### 2. INSTRUCTIONS

#### 2.1 Overview

This application is to be completed by those MA organizations that intend to offer an MA-PD plan during 2006. This application is to be submitted to CMS in conjunction with the documents (e.g., MA application or certification that MA contractor will meet new Part C requirements during 2006) required of all MA organizations (or MA Applicants) to qualify for participation in the Part C program during 2006. Please refer to the transition guidance for MA and Cost Plan sponsors posted on the CMS web site for instructions on the type of MA documentation your organization must provide to CMS to qualify to operate an MA plan during 2006.

## **2.2 Pre-Application Conferences**

CMS will conduct three conferences for potential Medicare Advantage (MA) and Prescription Drug Plan (PDP) sponsors to learn about requirements for plans under the MMA. The following conferences are planned:

- January 24-27, 2005 in Baltimore, Maryland
- January 31-February 1, 2005 in San Diego, California; and
- February 3-4, 2005 in New Orleans, Louisiana

The Baltimore conference is a four-day technical assistance and guidance conference for the Medicare Advantage and Prescription Drug industries on the new opportunities available under the Medicare Prescription Drug, Improvement, and Modernization Act. The conference will be conducted January 24-27, 2005 at the Radisson Lord Baltimore Hotel, Baltimore, Maryland. The conference will include sessions on the prescription drug plan, Medicare Advantage applications processes, regional PPOs, and employer group options. The training for potential drug benefit sponsors will be focused on completing the application. CMS strongly encourages the new and transitioning PACE programs, along with those with demonstration projects to attend the Baltimore conference. Information regarding registration, accommodations and other details for this conference can be accessed at <a href="http://cms.c2ti.com/industry">http://cms.c2ti.com/industry</a>. Registration closes for this conference on January 19, 2005.

In addition, conferences have also been scheduled for January 31-February 1 in San Diego and for February 3-4 in New Orleans for the convenience of PDP and MA representatives who are unable to attend the January 24-27, 2005 Industry Conference in Baltimore. These two conferences will have very similar content to the Baltimore conference but will be conducted with simultaneous PDP and MA sessions. Consequently, organizations that wish to hear about both MA and PDP at these conferences should plan to send two staff to cover both sessions. Information regarding registration, accommodations and other details for the San Diego and New Orleans conferences can be accessed at <a href="https://www.aspenxnet.com/partd">www.aspenxnet.com/partd</a>. Registration closes for these two conferences on January 21, 2005.

Please note that the San Diego and New Orleans conferences will cover the same PDP topics presented in Baltimore; however, the field conferences will not cover some MA topics such as appeals rules that are largely unchanged by the Medicare Modernization Act, but may nonetheless be of interest to potential new MA contractors. These topics will be covered in the Baltimore conference only. Therefore, CMS strongly encourages new MA organizations to attend the Baltimore conference.

## 2.3 Other Technical Support

CMS will conduct weekly technical support calls for Applicants from January 19, 2005 through June 2005, followed by bi-weekly calls. CMS operational experts (e.g., enrollment, information systems, marketing, bidding, formulary design, and coordination of benefits) will be available to discuss and answer questions on the agenda items for each meeting. Registration for the technical support calls can be found at <a href="https://www.aspenxnet.com/partd/usergroups">www.aspenxnet.com/partd/usergroups</a>.

## 2.4 Notice of Intent to Apply for New MA Organizations Only

To assist CMS in planning for the review of applications and to ensure that potential Applicants are notified of any additional guidance posted on the web, and for future correspondence, potential MA-PD Applicants should notify CMS of their intention to apply by 5:00 p.m. EST on **February 18, 2005**. Organizations that submit notices of intent to apply are not obligated to submit an application to CMS. However, CMS will not consider, under this solicitation process, an application for approval from an entity that has not submitted a timely "notice of intent to apply".

All <u>NEW</u> Medicare Advantage (MA) organizations are required to submit a notice of intent to apply to offer the Part D drug benefit. Existing Medicare managed care organizations that are transitioning in 2006 should NOT submit a notice of intent. MA Applicants seeking approval to offer multiple MA-PD plans should submit separate notices of intent to apply (for different type products) as instructed in Appendix V. This will allow CMS to generate separate pending contract numbers for each type of product.

There are three steps to submit a Notice of Intent to Apply:

Step 1	Complete Notice of Intent to Apply Form (Appendix I) and Email to CMS	Applicants must send a notice of its intent to apply by email to <a href="mailto:drugbenefitimpl@cms.hhs.gov">drugbenefitimpl@cms.hhs.gov</a> with "NOTICE OF INTENT" indicated in the subject field.		
Step 2	Complete CMS Connectivity Request Form (Appendix II) and Email to CMS	As part of the notice of intent submission, Applicant must also complete the CMS Connectivity Request form, which is necessary to conduct enrollment transactions. Complete and submit it at the same time as the notice of intent to apply to the email address: <a href="mailto:mdcn@cms.hhs.gov">mdcn@cms.hhs.gov</a> .  Questions about this form may also be directed to the same e-mail resource.		
Step 3	Complete Application for Access to CMS Computer Systems (located on CMS website) and Email and Mail to CMS	Applicant must also submit the Application for Access to CMS Computer Systems form (found on the CMS website www.cms.hhs.gov/mdcn/access.pdf).  Please see Instructions for Accessing CMS Systems (Appendix III) for instructions on completing the Application for Access to CMS Computer Systems form.  Document should be:  1. Emailed to drugbenefitimpl@cms.hhs.gov with "ACCESS TO CMS COMPUTER SYSTEMS" indicated in the subject field; and  2. Mailed as a hard-copy with original signature to:		

Note: If an Applicant Entity is submitting more than one notice of intent, Steps 2 and 3 above only need to be completed once, not multiple time with each notice.

## 2.5 Instructions and Format of Qualifications

#### **Instructions**

In preparing your application in response to the prompts in Section 3.0 of this solicitation, please mark "Yes" or "No" in sections organized with that format.

In many instances Applicants are directed to affirm that they will meet particular requirements by indicating "Yes" next to a statement of a particular Part D program requirement. By providing such attestation, an Applicant is committing its organization to complying with the relevant requirements as of September 15, 2005, unless an alternative date is noted in Section 3.0.

Additional supporting documentation is notated in the following manner throughout the application and is to be submitted as follows:

- 1. Appendices: documents supplied by CMS that are contained at the end of this application. They are to be completed by the Applicant and returned to CMS as indicated.
- 2. Attachments documents that are to be created and/or supplied by the Applicant and sent to CMS with the application. Attachments are to be used <u>only</u> when the application does not indicate to respond directly below the question. (i.e. Pharmacy Lists, subcontracts, etc.)

More specifically, Pharmacy Lists requested in Section 3.4, should only be submitted electronically on a Computer Diskette (CD) using Microsoft Excel (see Format section below for instructions on creating the CDs and Section 3.4 for specific information on creating the pharmacy lists). Due to the amount of data hard copies of these lists should not be included with the application.

Legal documents such as subcontracts should be provided in hard copy as an attachment to the application. They should also be provided on the CD associated with the relevant application section. The CD identification should include the appendix number.

CMS will check the application for completeness shortly after its receipt. We will notify Applicants of any deficiencies and afford them the opportunity to amend their applications.

While MA-PD sponsors are not required to begin providing the Part D benefit until January 1, 2006, CMS has established the September 15, 2005 deadline to allow adequate time for sponsors to cure any operational deficiencies before beneficiaries become entitled to Part D services. As with all aspects of a MA-PD sponsor's operations under its contract with CMS, we may verify a sponsor's compliance with qualifications it attests it will meet, through on-site visits at the MA-PD sponsor's facilities as well as through other program monitoring techniques. Failure to meet the requirements attested to in the Applicant's response to this solicitation and failure to operate its Part D plan(s) consistent with the requirements of the applicable statutes, regulations, and the Part D contract may delay a MA-PD sponsor's marketing and enrollment activities or, if corrections cannot be made timely, disqualify it from participation in the Part D program.

An individual with legal authority to bind the Applicant shall sign and submit the certification found in Section 4.0. CMS reserves the right to request clarifications or corrections to a submitted application. Failure to provide requested clarifications within a 2-day period could result in the applicant receiving an intent to deny the application, in which case, the Applicant will then have 10 days to seek to remedy its application. This solicitation does not commit CMS to pay any cost for the preparation and submission of an application.

#### **Format**

- To assure that each CMS review panelist receives the application in the manner intended by the applicant, Applicants should deliver a total of four (4) hard copies of the written application and supporting documentation.
- All hard copies should be in separate 3-ring binders. Tab indexing should be used to identify all of the major sections of the application. Page size should be 8 ½ by 11 inches and the pages should be numbered. Font size should be 12 point.
- One application should be clearly marked, "Original" and contain all original signed certifications requested in the application.
- Additionally, the Applicant must submit the written application and supporting
  documentation electronically using (CDs). This will support the review of the
  application by different CMS components. The Applicant must submit 4 sets of
  the 5 CDs identified below. Each set should be inserted inside of each hard copy
  application being submitted.

CD NUMBER	CONTENTS ON CD				
CD #1	Entire Application and Supporting Documentation – including Appendices, and Attachments ( <i>Do Not Include Pharmacy Lists</i> )				
CD #2	Subsection 3.1.1and Subsection 3.1.2 and related Appendices and Attachments				
CD #3	Subsection 3.1.3 and Section 3.10 and related Appendices and Attachments				
CD #4	Section 3.3 and Section 3.4 and related Appendices and Attachments (includes Pharmacy Lists)				
CD #5	Section 3.12 and related Attachments				

- All responses should be completed in Microsoft Word (in a version that is compatible with Office 2003). Attachments (such as existing contracts) can be submitted in Microsoft Word (in a version that is compatible with Windows 2003) or as a PDF file. Pharmacy lists should be created in Microsoft Excel (in a version that is compatible with Office 2003).
- Each CD must be clearly labeled with the information in the table below:

Applicant's Organization Name	
CMS Identification Number	
CD Number (as notated above)	
Section and/or Subsection Number and Name	

• Failure to submit an application consistent with these instructions may delay its review by CMS and could result in receipt of an intent to deny.

• If your organization is a transitioning or new (local) Medicare Advantage Organization applications must be sent to:

Centers for Medicare & Medicaid Services (CMS)

Marietta Mack

Multi-Purpose Room

Attn: Part C & Part D Application

7500 Security Boulevard

Baltimore, Maryland 21244-1850

• If your organization is a new Medicare Advantage Regional PPO (MA-RPPO) your Part C application should be mailed to the address identified in the MA-RPPO application and the Part D section be sent to:

Centers for Medicare & Medicaid Services (CMS)

Marietta Mack

Multi-Purpose Room

Attn: Regional PPO Part D Application

7500 Security Boulevard

Baltimore, Maryland 21244-1850

- Applications mailed through carriers that do not have CMS Security Clearance could be delayed due to clearance processing. Carriers with CMS Security Clearance include Federal Express and Airborne Express.
- CMS will not review applications received after 5:00 P.M. EST on March 23, 2005.

#### Single Application Representing Multiple Plans

Part D Plans of the same type, offered by the same legal entity, regardless of their service area may be represented in a single application. There are three types of Part D solicitations for which applications are due on March 23, 2005; they are PDP, MA-PD, and Cost Plan solicitations. Entities that intend to offer a combination of these types of Part D plans must submit a separate application for each type. (Employer and PACE plan sponsors will also have separate solicitations.) For example, an MA-PD and PDP product may not be represented in the same application. Also, entities intending to offer both local MA-PD and Regional PPO plans must submit separate MA-PD applications. If an Applicant's response to any inquiry in the application is different for one plan than another, this delineation must be clearly identified at the beginning of each section of the application where such delineation is made. The Applicant must use consistent nomenclature to distinguish between the plans as necessary throughout the application. The Applicant must submit a face sheet to the application indicating that multiple plans are represented in the application, whether plan-specific delineations are made, the nomenclature to distinguish among the plans, and in what sections and subsections of the application.

## Applicant Entity Same as Contracting Entity

The legal entity that submits this application must be the same entity with which CMS enters into a Part D contract, or in the case of an MA-PD and Cost Plan sponsor, the same legal entity seeking an addendum to an MA or Cost Plan contract. An entity that qualifies for a Part D contract, or for an addendum to an MA or Cost Plan contract, may offer multiple plans of the same type (e.g. PDP, MA-PD, or Cost Plan) in the service area described in the application.

## Joint Enterprise as Regional PPO Applicant and Contracting Entity

When reviewing MA-PD applications from potential MA Regional PPO sponsors (RPPOs), CMS will recognize as Applicants those joint enterprises formed by agreement among multiple state-licensed organizations (or organizations that have applied to CMS for a licensure waiver) for the purpose of administering a Medicare Prescription Drug Plan in at least one entire PDP region. Each member of the joint enterprise will be contractually liable to CMS for the administration of the Part C and Part D portions of their Medicare benefit plans in the State(s) in which it is licensed or for which it has received a CMS licensure waiver.

The joint enterprise need submit only one MA-PD application on behalf of the enterprise's member organizations and such application shall represent a uniform benefit. However, the information requested in Section 3.1 of this solicitation must be provided for each member of the joint enterprise, with separate accompanying Appendices as necessary. For example, each joint enterprise member must provide identifying information about its organization, copies of its executed contracts with entities performing critical tasks related to the delivery of the Part D benefit, and information related to its business integrity. The responses provided in the remainder of the application may be made once by the joint enterprise applicant and will be considered binding on each member of the joint enterprise. Also, a separate certification statement, shown in Section 4.0, must be provided for each joint enterprise member organization. Each certification statement must be signed by an individual specifically granted the authority to bind the member organization.

Joint enterprise applicants are required to submit to CMS for approval, as part of this application, a copy of the executed agreement among the joint enterprise member organizations. Please see Section 3.1.1.G for instructions concerning this requirement.

Upon CMS's determination that the members of the joint enterprise are qualified to enter into a Part D addendum to the Applicant's Medicare Advantage Regional PPO contract and approval of the bid(s) submitted by the joint enterprise, CMS will enter into a multiple-party MA Part D addendum signed by authorized representatives of CMS and each member of the joint enterprise.

## 2.6 Submission Software Training

Applicants will use the CMS Health Plan Management System (HPMS) during the application, formulary, and bid processes. Applicants will be required to enter contact and other related information collected in HPMS in order to facilitate the application review process.

Applicants will be required to upload their plan formularies to HPMS using a pre-defined file format and record layout. CMS plans to release the formulary upload functionality on March 28, 2005. Formularies are due to CMS on April 18, 2005.

In order to prepare plan bids, Applicants will use HPMS to define their plan structures and associated plan service areas and then download the Plan Benefit Package (PBP) and Bid Pricing Tool (BPT) software. For each plan being offered, Applicants will use the PBP software to describe the detailed structure of their Part D benefit and the BPT software to define their bid pricing information. The formulary must accurately crosswalk to the PBP. The combination of the PBP and BPT for a plan comprises a bid. CMS anticipates releasing the HPMS bid creation functionality, including the PBP and BPT software, on April 8, 2005.

Once the PBP and BPT software has been completed for each plan being offered, Applicants will upload their bids to HPMS. CMS anticipates releasing the PBP and BPT bid upload functionality on May 20, 2005. Applicants will be able to submit uploads to HPMS on their PBP or BPT one or more times between May 20, 2005 and the CY 2006 bid deadline of June 6, 2005. CMS will use the last successful upload received for a plan as the official bid submission.

CMS will provide technical instructions and guidance upon release of the HPMS formulary and bid functionality as well as the PBP and BPT software. In addition, systems training will be available at the Bid Training in April 2005.

## 2.7 System and Data Testing with CMS

#### **HPMS**

MA-PD organizations will use HPMS to communicate with CMS in support of the application process, formulary submission process, bid submission process, ongoing operations of the Part D program, and reporting and oversight activities. MA-PD sponsors are required to secure access to HPMS in order to carry out these functions. Transitioning MA organizations have HPMS connectivity and are not required to reestablish their HPMS connectivity.

New MA Applicants should reference *Instructions for Accessing CMS Systems* (Appendix III) for instructions on establishing access to HPMS. Establishing connectivity will ensure that Applicants have sufficient time to prepare and submit their formularies to HPMS by April 18, 2005 and their PBPs and BPTs by June 6, 2005.

#### Enrollment

MA-PD sponsors are required to establish connectivity to CMS via the AT&T Medicare Data Communications Network (MDCN). This secure network allows direct transmission of enrollment information to CMS for processing.

- CMS recommends that MA-PD sponsors contact AT&T to establish connectivity 3 months prior to beginning file transmissions.
- AT&T can be contacted on 1-800-905-2069.
- MA-PD sponsors must also obtain a CMS User ID and password.
- Download the User Access Form located at <a href="www.cms.hhs.gov/mdcn/access.pdf">www.cms.hhs.gov/mdcn/access.pdf</a>, complete it and mail it to your assigned plan manager.

CMS will communicate a beneficiary's eligibility for enrollment in a Part D plan as well as for a low-income subsidy. CMS will also determine whether a beneficiary must pay a late enrollment penalty. CMS will record the results of this processing and reply to the MA-PD sponsor. Monthly membership listings will be made available for reconciliation purposes. They will be downloaded using the MDCN connectivity. Similarly, MA-PD sponsors will be required to report disenrollment information to CMS.

A test environment will be established to accept, process, and reply to MA-PD transmissions. In addition, Help Desk staff will be available to assist MA-PD sponsors in this process and to trouble-shoot reported problems. Testing is expected to occur during the summer of 2005. Specific instructions will be provided prior to that time.

#### Payment for MA-PD Sponsors

Payments will be wired to sponsor accounts on the first business day of each month (or the last business day of the prior month if the first day of the month is not a business day). If your organization does not currently receive electronic payments from CMS, please submit the *Banking Information Form* (Appendix IV) so that payments can be transmitted to your account.

The monthly payment will include premiums that SSA or other agencies are deducting from beneficiary Social Security or other payments as well as those premiums CMS is paying on behalf of low-income individuals. Estimated monthly reinsurance subsidies (reinsurance being paid in the early years based on an estimate of reinsurance included in the bid), and low-income subsidies will also be included.

Monthly beneficiary-level Part D payment reports will be available detailing the components of each payment for reconciliation purposes. MA-PD plan level reports summarizing the monthly payment and any applicable adjustments will also be provided. MA-PD sponsors will download these reports via their MDCN connectivity.

Test versions of these reports will be provided in late summer of 2005. Specific testing instructions will be provided at a later date.

## 2.8 Summary Instruction and Format for Part D Bids

Each MA-PD Applicant must submit to CMS a bid for each prescription drug plan it intends to offer. Applicants using this solicitation must apply to offer full risk Part D plans. Applicants must submit their formularies to HPMS on or before April 18, 2005 and the PBPs and BPTs on or before June 6, 2005.

## 2.8.1 Format of Part D Bids

#### Bid Submission Sections Due Prior to June 6, 2005

To facilitate the timely review of all the bid submissions, CMS expects to require Applicants to submit the portion of their bid related to formulary and covered drugs by April 18, 2005. CMS will review areas of each proposed drug plan formulary by tier and drug availability and evaluate each element against evidence-based standards such as widely accepted treatment guidelines. Elements will include, but may not be limited to the list of drugs, the categories and classes, tier structures (not cost sharing), and utilization management tools such as quantity limits, step therapy, and prior authorization. CMS will make the review criteria available to Applicants well in advance of the date Applicants must submit this information to CMS. Outliers will be selected for further review of the formulary development process prior to CMS approval of the bid. CMS will make reasonable efforts to inform Applicants of their outliers so that they may substantiate their offering. If such substantiation is not satisfactory to CMS, the Applicant will be given the opportunity to modify the formulary. CMS intends to complete as much of this work as possible before the June 6, 2005, PBP and BPT submissions so that any modification may be reflected in those documents.

#### Bid Submission Due June 6, 2005

The Applicant's bid will represent the expected monthly cost to be incurred by the Applicant for qualified prescription drug coverage in the approved service area for a Part D-eligible beneficiary on a standardized basis. The costs represented in each bid should be those for which the Applicant would be responsible. These costs would not include payments made by the plan enrollee for deductible, coinsurance, copayments, or payments for the difference between the plan's allowance and an out-of-network pharmacy's usual and customary charge. The bid will require the separate identification, calculation, and reporting of costs assumed to be reimbursed by CMS through reinsurance. CMS requires that the bid represent a uniform benefit package based upon a uniform level of premium and cost sharing among all beneficiaries enrolled in the plan. The benefit packages submitted must be cross walked appropriately from the formulary. Pursuant to 423.505(k)(4), the CEO, CFO, or a

delegee with the authority to sign on behalf of one of these officers, and who reports directly to such officer, must certify (based on best knowledge, information and belief) that the information in the bid submission, and assumptions related to projected reinsurance and low-income cost sharing subsidies, is accurate, complete, and truthful, and fully conforms to the requirements in section 423.265 of the regulations. In addition, the pricing component of the bid must also be certified by a qualified actuary.

## 2.8.2 CMS Review of Part D Bids

CMS will evaluate the bids based on four broad areas: 1) administrative costs, 2) aggregate costs, 3) benefit structure, and 4) plan management. CMS will evaluate the administrative costs for reasonableness in comparison to other bidders. CMS will also examine aggregate costs to determine whether the revenue requirements for qualified prescription drug coverage are reasonable and equitable. In addition, CMS will review the steps the MA-PD sponsor is taking to control costs, such as through various programs to encourage use of generic drugs. Finally, CMS will examine indicators concerning plan management, such as customer service.

CMS is also required to make certain that bids and plan designs meet statutory and regulatory requirements. We will conduct an actuarial analysis to determine whether the proposed benefit meets the standard of providing qualified prescription drug coverage. Also, CMS will review the structure of the premiums, deductibles, copayments, and coinsurance charged to beneficiaries and other features of the benefit plan design to ensure that it is not discriminatory (that is, that it does not substantially discourage enrollment by certain Part D eligible individuals).

## 2.8.3 Overview of Part D Bid Negotiation

CMS expects to evaluate the reasonableness of bids submitted by MA-PD sponsors by means of an actuarial valuation analysis. This requires evaluating assumptions regarding the expected distribution of costs, including average utilization and cost by drug coverage tier. CMS could test these assumptions for reasonableness through actuarial analysis and comparison to industry standards and other comparable bids. Bid negotiation could take the form of negotiating changes upward or downward in the utilization and cost per script assumptions underlying the bid's actuarial basis. CMS could exercise our authority to deny a bid if we do not believe that the bid and its underlying drug prices reflect market rates.

## 2.9 Standard Contract with MA-PD Sponsors

Successful Applicants will be deemed qualified to enter into a Part D addendum to their Medicare Advantage contract. Under this addendum the MA-PD sponsor will be authorized to operate one or more Medicare prescription drug plans. Only after the

qualified Applicant and CMS have reached agreement on the Applicant's bid submissions will the Applicant be asked to execute its Part D addendum.

The Part D addendum will be for an initial 16-month term (September 1, 2005 through December 31, 2006), renewable after the initial term for one-year periods at the end of each calendar year at the option of both CMS and the Applicant. The initial 16-month period is intended to ensure that Part D Sponsors meet enrollment and marketing requirements prior to the January 1, 2006 start date of the first Part D benefit period. The text of the standard contract will be provided in the spring of 2005.

## 2.10 Additional Information Available

To assist Applicants in preparing the retail pharmacy network access analysis, CMS has posted a data file at <a href="http://www.cms.hhs.gov/pdps/">http://www.cms.hhs.gov/pdps/</a> that contains total Medicare beneficiary counts by ZIP code. This file will also include markers for MA and PDP regions. The file name is "MCareEnrbyZip062004.zip."

To assist Applicants in preparing their long-term care (LTC) pharmacy access analysis, CMS has provided Applicants with a data file at <a href="http://www.cms.hhs.gov/pdps/">http://www.cms.hhs.gov/pdps/</a> that contains information on LTC facility location (address, state, zip code, MA region, and PDP region) and certified bed count. The file name is "LTCFacilities012005.zip."

To assist Applicants in preparing their bids, CMS has made the following drug use and drug spending information available at http://www.cms.hhs.gov/pdps/:

- Individual-level data from the Medicare Current Beneficiary Survey (MCBS)
- Continuance tables based on MCBS data
- Medicaid data based on 48 states
- State-level expenditure adjusters based on Federal retirees in a national plan; Medicaid drug expenditure data for most states
- Drug costs imputed from the MCBS to a 5 percent sample of Medicare beneficiaries

## **2.11 Protection of Confidential Information**

Applicants can always seek to protect their information under the Freedom of Information Act and label truly proprietary information "confidential" or "proprietary." When information is so labeled, the Applicant is required to explain the applicability of the FOIA exemption they are claiming. When there is a request for information that is designated by the Applicant as confidential or that could reasonably be considered exempt under Exemption 4, CMS is required by its FOIA regulation at 45 C.F.R. §5.65(d) and by Executive Order 12,600 to give the submitter notice before the information is disclosed. To determine whether the Applicant's information is protected by Exemption 4, the Applicant must show that—(1) disclosure of the information is likely to impair the government's ability to obtain necessary information in the future; (2)

disclosure of the information is likely to cause substantial harm to the competitive position of the submitter; or (3) the records are considered valuable commodities in the marketplace which, once released through the FOIA, would result in a substantial loss of their market value. Consistent with our approach under the Medicare Advantage program, we would not release information under the Medicare Part D program that would be considered proprietary in nature.

## 2.12 Waivers

CMS is authorized to grant waivers of Part D program requirements where such a requirement conflicts with or duplicates a Part C requirement, or where granting such a waiver would improve the MA-PD sponsor's coordination of Part C and Part D benefits. Accordingly, CMS has identified the waivers it is granting to all MA-PD sponsors in the chart shown in *Summary of PDP Application Requirements Waived for Medicare Advantage Prescription Drug (MA-PD) Applicants* (Appendix V). As a result of these CMS-granted waivers, the MA-PD sponsor application is less comprehensive than the PDP sponsor application. These waivers will be reflected in each MA-PD sponsor's Part D addendum.

<u>Applicant Requests for Additional Waivers</u>: CMS may grant additional waivers upon an MA-PD sponsor's request, provided that the waivers may be justified as duplicative of or conflicting with Part C requirements, or improving the coordination of Part C and Part D benefits. Any waiver granted by CMS will apply to all similarly situated MA-PD sponsors.

For each waiver request, the Applicant must provide, as an attachment to its MA-PD application and on a CD per instructions in Section 2.5, a statement that includes:

- 1. The Part D regulation reference;
- 2. The appropriate waiver criteria (e.g., duplicative, conflicts, improves benefit coordination);
- 3. A discussion of how the requested waiver meets at least one of the three waiver criteria.

CMS will notify Applicants whether their requests were approved as part of the notice of MA-PD application approval they will receive in May 2005. As noted above, waivers granted will be reflected in each MA-PD sponsor's Part D addendum.

Where this application directs the Applicant to attest that it will meet a particular Part D requirement for which the Applicant has requested a waiver, the Applicant should check both the "Yes" box and the "Waiver Requested" box. In the event that CMS does not approve a particular waiver, the Applicant will still have attested that it will meet all the applicable Part D program requirements and remain eligible to enter into a Part D addendum upon approval of its bids at the end of the summer of 2005. This process will prevent Applicants from having to submit additional application responses after the original March 23, 2005 deadline. If, as a result of CMS' denial of its waiver request, the

Applicant no longer intends to offer a Part D benefit plan, the Applicant must notify CMS in writing on or before June 30, 2005. CMS will not execute a Part D addendum with Applicants that submit such a notice. This notice of withdraw should be sent to:

Centers for Medicare & Medicaid Services (CMS)
Center for Beneficiary Choices
Attention: Marietta Mack
7500 Security Boulevard
Mail Stop S1-05-06/Location S2-04-05
Baltimore, Maryland 21244-1850

#### 3. APPLICATION

Note: Nothing in this application is intended to supersede the regulations at 42 CFR Part 423. Failure to reference a regulatory requirement in this application does not affect the applicability of such requirement, and MA-PD sponsors and/or Applicants are required to comply with all applicable requirements of the regulations in Part 423 of 42 CFR.

# 3.1 Applicant Experience, Contracts, Licensure and Financial Stability

SPECIAL INSTRUCTIONS FOR JOINT ENTERPRISE REGIONAL PPO APPLICANTS: If an application is being submitted by a joint enterprise, as described above in Section 2.6, a separate set of responses to the requirements in Section 3.1. must be provided as part of this application by each member organization of the joint enterprise.

#### 3.1.1 Management and Operations

#### A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'		NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN:			
<ol> <li>Applicant is applying to operate as a MA-PD Sponsor.</li> <li>Applicant is applying to operate as an MA-PD sponsor.</li> </ol>			
3. Applicant is a non-governmental legal entity that agrees to abide by the terms of a Medicare Prescription Drug Plan addendum to its Medicare Advantage contract with CMS.			

B. Describe below your staffing plan for the operation of your Part D benefit plan(s). In particular, discuss the number of staff assigned to the following activities:

- Financial
- Marketing
- Furnishing of Prescription Drug Services
- Quality Assurance
- Fraud and Abuse
- Medication Therapy Management
- Drug Utilization Management
- Claims Processing

C. Complete the form below(s) to identify each of the entities with which you subcontract to serve the functions identified in Subsection 3.1.2 A. If more than one subcontractor has been engaged to meet these functions, identify each of the subcontractors within the relevant requirement column. Copy and paste the form, if you need additional space:

IDENTIFY YOUR SUBCONTRACTOR BY PROVIDING THE FOLLOWING INFORMATION					
Full Legal Organization's Name of Subcontractor: Function(s) Contracted for:			Function(s) Contracted for:		
Full Address of Subcontractor's H	eadquarters (Street, City, Stat	te, Zip):			
Name of Chief Operating Officer:					
Name of Chief Financial Officer:					
Type of Ownership:					
☐ Sole Proprietorship	☐ Sole Proprietorship ☐ Partnership				
☐ Publicly-Traded Corporation	oration				
Name of Subcontractor's Parent Organization, if any:					
State in Which Your Subcontracto	r is Incorporated or Otherwise	Organized t	to do Business:		
Federal Taxpayer Identification No	Federal Taxpayer Identification Number:				
PROVIDE INDIVIDUAL WHO WILL SIGN THE MEDICARE CONTRACT WITH THE MA-PD APPLICANT. THIS					
PERSON MUST BE AUTHORIZED TO ACT FOR THE SUBCONTRACTOR ENTITY:					
Name of Individual:	Name of Individual: Title:				

# D. Provide as attachments (as instructed in Section 2.5) copies of executed contracts with each subcontractor identified in the above tables (3.1.1 C) that:

- 1. Clearly identify the parties to the contract (or letter of agreement);
- 2. Describe the functions to be performed by the subcontractor, as well as any reporting requirements the subcontractor has to the Applicant;
- 3. Contain language clearly indicating that the subcontractor has agreed to participate in your Medicare Prescription Drug Benefit program (except for a network pharmacy if the existing contract would allow participation in this program), and flow-down clauses requiring their activities be consistent and comply with the Applicant's contractual obligations as a PDP sponsor;
- 4. Contain language describing the services to be performed in a manner that encompasses the services required to support the Medicare Prescription Drug Benefit program;
- 5. Describe the payment the subcontractor will receive for performance under the contract, if applicable;
- 6. Are for a term of at least the first year of the program. (Please note that first year contracts between the Applicant and an entity performing Part D enrollment functions on behalf of the Applicant should have a start date no later than November 15, 2005, the first date of the first annual election period for Part D enrollments to be made effective January 1. 2006. Future year terms are January 1 to December 31.);
- 7. Are signed by a representative of each party with legal authority to bind the entity;
- 8. Contain language obligating the subcontractor to abide by all applicable Federal and State laws and regulations and CMS instructions;
- Contain language obligating the subcontractor to abide by State and Federal privacy and security requirements, including the confidentiality and security provisions stated in the regulations for this program at 42 CFR §423.136;

- 10. Contain language ensuring that the subcontractor will make their books and other records available in accordance with 42 CFR 423.505 (i)(2). Generally stated these regulations give HHS, the Comptroller General, or their designees the right to inspect, evaluate and audit books and other records and that these rights continue for a period of 10 years from the final date of the contract period or the date of audit completion, whichever is later.
- 11. Contain language that the subcontractor will ensure that beneficiaries are not held liable for fees that are the responsibility of the PDP sponsor;
- 12. Contain language that if the Applicant, upon becoming a PDP sponsor, delegates an activity or responsibility to the subcontractor, that such activity or responsibility may be revoked if CMS or the PDP sponsor determines the subcontractor has not performed satisfactorily. The subcontract may include remedies in lieu of revocation to address this requirement;
- 13. Contain language specifying that the Applicant, upon becoming a PDP sponsor, will monitor the performance of the subcontractor on an ongoing basis; and
- 14. If the subcontractor will establish the pharmacy network or select pharmacies to be included in the network, contain language that the PDP sponsor retains the right to approve, suspend, or terminate any arrangement with a pharmacy.

Note: While CMS is only requesting certain contracts, elements 2, 8, 10, 11, 12, and 13 of section 3.1.1 D are required in <u>all</u> the Applicants contracts necessary to provide the Part D benefit.

- E. Provide as an attachment the signed certification in Appendix VIII. The certification allows the Applicant to verify that the subcontracts submitted under 3.1.1D meet all of the requirements identified in 3.1.1D.
- F. Provide electronic lists of the subcontract citations demonstrating that the requirements of Section 3.1.1D are included in the subcontracts. Submit this data by creating a spreadsheet in Microsoft Excel that mimics Appendix IX. Provide this attachment on a CD as instructed in Section 2.5.
- G. SPECIAL REQUIREMENT FOR JOINT ENTERPRISE APPLICANTS: Joint Enterprise Applicants must provide as part of their application a copy of the agreement executed by the State-licensed entities describing their rights and responsibilities to each other and to CMS in the operation of a Medicare Part D benefit plan. Such an agreement must address at least the following issues:
  - Termination of participation in the joint enterprise by one or more of the member organizations; and
  - Allocation of CMS payments among the member organizations.

Further guidance may also be provided regarding the terms and conditions of the joint enterprise contract.

# 3.1.2 Experience and Capabilities

# A. Complete the table below:

AF	PLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' $% \left( \mathbf{r}^{\prime }\right) =\left( \mathbf{r}^{\prime }\right) $			NO	Waiver?
OF	OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN	THE RELEVANT COLUMN.			
	Applicant and/or one of its subcontractors currently operates a pharmacy benefit program that performs adjudication and processing of pharmacy claims at the point of sale.			
2.	Applicant and/or one of its subcontractors currently operates a pharmacy benefit program that performs negotiation with prescription drug manufacturers and others for rebates, discounts, or other price concessions on prescription drugs.			
3.	Applicant and/or one of its subcontractors currently operates a pharmacy benefit program that performs administration and tracking of enrollees' drug benefits in real time.			
4.	Applicant and/or one of its subcontractors currently operates a pharmacy benefit program that performs coordination with other drug benefit programs, including, for example, Medicaid, state pharmaceutical assistance programs, Medigap, or other insurance.			
5.	Applicant and/or one of its subcontractors currently develops and maintains a pharmacy network.			
6.	Applicant and/or one of its subcontractors currently operates a pharmacy benefit program that operates an enrollee grievance and appeals process.			
7.	Applicant and/or one of its subcontractors currently operates a pharmacy benefit program that performs customer service functionality, that includes serving seniors and persons with a disability.			

B. As part of the discussion of the experience described immediately above, please indicate the 2004 business volumes your organization has generated in operating your benefit by completing the table below:

PHARMACY-RELATED ENTITIES INSURED PHARMACY BENEFITS (#1)						
Metric for Calendar Year 2004	Retail	Mail				
Covered Lives (#2)						
Senior Lives (if available)						
Claims Processed or Number of Total Utilization	Check: ☐ Claims Processed, or ☐ Total Utilization	Check: ☐ Claims Processed, or ☐ Total Utilization				
Drug Spending Managed						
IF THE ENTITY UNDERWENT SIGNIFICANT CHANGE IN 2004, OR IT EXPECTS IN 2005 TO HAVE						
SUBSTANTIALLY DIFFERENT BUSINESS VOLUMES, PLEASE COMMENT BELOW AND PROVIDE 2005						
PROJECTED VOLUMES IN ADDITION TO YOUR BUSINESS VOLUMES FOR 2004:						

#1 Exclusive of any prescription drug discount card programs

- #2 a) Covered lives are discrete individuals for whom there is verifiable information / documentation that, on audit, would demonstrate their enrollment in the insured benefits program through either hard copy signed agreements, payment of insurance premiums, or some comparable verification. Covered lives are not demonstrated or accounted for by hits on a Web site or number of prescriptions filled or for which a claim was processed. Nor are covered lives demonstrated by counting signed agreements and multiplying by an average family size (if a family premium was paid, the "family" is 2 people; unless the organization can document additional family members are included).
- b) To calculate covered lives, use most recent data. Applicants should pick a point in time within the previous 12 months and provide the number of unique lives. Please specify month for point in time used.

## 3.1.3 Business Integrity

## A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO THE FOLLOWING QUALIFICATION TO BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' OR 'NO' TO THE FOLLOWING QUALIFICATION BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:		NO	Requesting Waiver? Yes or No
Applicant and its affiliated companies, subsidiaries or subcontractors, subcontractor staff, any member of its board of directors, any key management or executive staff, or any major shareholder agree that they are bound by 45 CFR Part 76 and attest that they are not excluded by the Department of Health and Human Services Office of the Inspector General or by the General Services Administration.			

B. List any past or pending, if known, investigations, legal actions, or matters subject to arbitration brought involving the Applicant (and Applicant's parent firm if applicable) and its subcontractors, including any key management or executive staff, or any major shareholders (5% or more), by a government agency (state or federal) over the past three years on matters relating to payments from governmental entities, both federal and state, for healthcare and/or prescription drug services. Provide a brief explanation of each action, including the following:

- 1) Legal names of the parties;
- 2) Circumstances;
- 3) Status (pending or closed);
- 4) If closed, provide the details concerning resolution and any monetary payments; and
- 5) Settlement agreements or corporate integrity agreements.

## 3.2 Benefit Design

## 3.2.1 Pharmacy and Therapeutics (P&T) Committee

#### A. Complete the form below:

INDICATE IF THE APPLICANT ANTICIPATES SUBMITTING A FORMULARY				
Note: CMS is using this information to understand how many formularies it may need to review beginning April 18, 2005.				
Check Yes or No				
☐ Yes ☐ No				
If yes, indicate how many formularies you anticipate to submit:				
If no, indicate if all drugs will have the same cost-sharing? ☐ Yes ☐ No				

## B. Complete the form below:

APPLICANT MUST ATTEST 'YES' TO THE FOLLOWING QUALIFICATION TO BE APPROVED		
FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' OR 'NO' TO THE	YES	NO
FOLLOWING QUALIFICATION BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:		
Applicant will submit a formulary, if answered "No" to "Indicate if all drugs will have the same cost-sharing" in 3.2.1 A above.		

## C. Complete the form below:

PROVIDE THE NAMES OF THE MEMBERS OF YOUR ORGANIZATION'S P&T COMMITTEE. INDICATE WHICH MEMBERS ARE PRACTICING PHYSICIANS OR PRACTICING PHARMACISTS. FURTHER, INDICATE WHICH MEMBERS ARE EXPERTS IN THE CARE OF THE ELDERLY OR DISABLED, AND FREE OF ANY CONFLICT OF INTEREST WITH YOUR ORGANIZATION AND PHARMACEUTICAL MANUFACTURERS. (APPLICANTS SHOULD MARK THE INFORMATION AS PROPRIETARY.) ADD ADDITIONAL ROWS AS NECESSARY

	Practice/Expertise  Mark an 'X' in Appropriate Column			Free of Any Conflict of Intere Type Yes or No		
Full Name of Member	Practicing Physician	Practicing Pharmacist	Elderly/Disabled Expert	With Your Organization?	With Pharmaceutical Manufacturers?	

## D. Complete the table below:

REPLY 'YES' OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A			Requesting
CHECKMARK IN THE RELEVANT COLUMN. IF APPLICANT INDICATED IN 3.1.2.A, 'YES,'	YES	NO	Waiver?
THAT APPLICANT IS PROVIDING A FORMULARY, THEN THE APPLICANT MUST			Yes or No
ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE APPROVED			
FOR A PART D ADDENDUM TO THE PART C CONTRACT. IF APPLICANT INDICATED '			
NO' IN 3.1.2 A, THAT IT IS NOT PROVIDING A FORMULARY AND REPLIES NO TO ANY			
OF THE ATTESTATIONS BELOW, THIS WILL NOT DISQUALIFY THE APPLICANT FROM			
A CONTRACT			
Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market.			
Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors.			
2. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy.			
3. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, generic substitution, and therapeutic interchange protocols.			
4. Applicant will adhere to P&T guidelines that will, from time to time, be promulgated with regard to such subject areas as membership, conflict of interest, meeting schedule, meeting minutes, therapeutic classes, drug review and inclusion, formulary management, utilization management and review,			

	formulary exceptions, and educational programs for providers.		
5.	Applicant's P&T committee will make a reasonable effort to review within 90		
	days, and will make a decision on each new chemical entity, and new FDA		
	clinical indicators, within 180 days of its release onto the market, or a clinical		
	justification will must be provided if this timeframe is not met.		
6.	Applicant's P&T committee will approve inclusion or exclusion of the therapeutic		
	classes in the formulary on an annual basis.		
7.	The majority of the membership of the Applicant's P&T committee shall be		
	practicing physicians and/or practicing pharmacists.		
	The control of the Andrew Copper Copper William Control of the Copper Co		
8.	The state of the s		
	practicing physician and at least one practicing pharmacist who are free of		
	conflict with respect to the Applicant organization and pharmaceutical		
_	manufacturers.		
9.	The membership of the Applicant's P&T committee will include at least one		
	practicing physician and at least one practicing pharmacist who are experts in		
	the care of the elderly or disabled persons.		
10	). Applicant's P&T committee will recommend protocols and procedures for the		
	timely use of and access to both formulary and non-formulary drug products.		

# 3.2.2 Utilization Management Standards

If the Applicant is a MA Private Fee for Service (MA-PFFS) organization, as described in 42 CFR §422.4 (a) (3), the utilization management requirements used as the basis for this sub-section of the application do not apply (See 42 CFR §423.153 (e)). The Applicant should proceed to sub-section 3.2.3 "Quality Assurance and Patient Safety" of the application.

## A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN.			
Applicant maintains policies and procedures to prevent over-utilization and under-utilization of prescribed medications, including but not limited to the following elements:			
Compliance programs designed to improve adherence/persistency with appropriate medication regimens			
<ul> <li>Monitoring procedures to discourage over-utilization through multiple prescribers or multiple pharmacies</li> </ul>			
Quantity versus time edits			
Early refill edits			
Applicant maintains methods to ensure cost-effective drug utilization management. Examples of these tools include, but are not limited to:			
Step therapy			
Prior authorization			
Tiered cost-sharing			
Applicant makes enrollees aware of utilization management program requirements through information and outreach materials.			
4. Applicant develops incentives to reduce costs when medically appropriate such as, but not limited to encouragement of generic utilization.			

5.	Applicant will report to CMS data for UM standards in the manner prescribed by		
	CMS. (See Section 3.11 Reporting Requirements)		

## 3.2.3 Quality Assurance and Patient Safety

## A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN.			
Applicant establishes a quality assurance program that includes measures and reporting systems such as, but not limited to:     Reducing medication errors     Reducing adverse drug interactions			
2. Applicant performs drug utilization review at a minimum of what is specified in the regulation 42CFR 423.153 (c) (2) and (3).			
3. Applicant will ensure patient counseling is offered to enrollees, when appropriate.			
Applicant develops and implements internal medication error identification and reduction systems.			
Applicant ensures network pharmacies implement a method for maintaining upto-date enrollee information such as, but not limited to:			
6. Applicant will report to CMS data for QA standards in the manner prescribed by CMS. (See Section 3.13 Reporting Requirements)			
7. Applicant will establish appropriate transition policies and procedures for beneficiaries on drug regimens that are not on the plan's Part D formulary. These policies and procedures must address all the elements specified in formulary transition guidance to be provided by CMS in early March.			
8. The Applicant agrees to submit to CMS on April 18, 2005 a description of the organization's approach to transitioning beneficiaries on drug regimens that are not on the plan's Part D formulary (see note below).			
9. Applicant will establish appropriate policies and procedures for addressing the immediate needs of enrollees who are LTC residents in situations where there is a disparity between the Part D requirements and the Medicare conditions of participation (COPs) for LTC facilities.			
10. The Applicant agrees to submit to CMS on April 18, 2005 a description of the organization's approach to address the immediate needs of enrollees who are LTC residents in situations where there is a disparity between the Part D requirements and the Medicare conditions of participation for LTC facilities. (see note below)			

**NOTE**: The answer to Item #8 and #10 will be collected in HPMS and should be submitted with the Applicant's formulary under the exception /notes transition word file provided in HPMS. The format will be delineated in HPMS user instructions that will be released in March.

### 3.2.4 Medication Therapy Management

If the Applicant is a MA Private Fee for Service (MA-PFFS) organization, as described in 42 CFR §422.4 (a) (3), the medication management standards used as the basis for this sub-section of the application do not apply (See 42 CFR §423.153 (e)). The Applicant should proceed to sub-section 3.2.5 "Electronic Prescription Program" of the application.

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN.			
Applicant will develop and implement Medication Therapy Management (MTM)     Program designed to :			
<ul> <li>Ensure optimum therapeutic outcomes for targeted beneficiaries through improved medication use</li> </ul>			
<ul> <li>For targeted beneficiaries, reduce the risk of adverse events, including adverse drug interactions</li> </ul>			
Applicant will develop the MTM program in cooperation with licensed and practicing pharmacists and physicians.			
3. Applicant will target beneficiaries for enrollment in the MTM program based on using all three of the following criteria:			
<ul> <li>Beneficiary must have multiple chronic diseases, such as diabetes, asthma, congestive heart failure, hyperlipidemia, and</li> </ul>			
hypertension (list to be determined by plan); • Beneficiary must be taking multiple covered Part D medications			
<ul> <li>(specifics to be determined by plan); and</li> <li>Beneficiary must be identified as likely to incur annual costs for covered part D drugs that exceed \$4,000.00</li> </ul>			
4. Applicant will establish appropriate policies and procedures for their MTM program, including, but not limited to, services, payments and criteria used for identifying beneficiaries eligible for the MTM program.			
5. The Applicant agrees to submit to CMS on April 18, 2005 a description of their MTM program including, but not limited to, policies, procedures, services, payments and criteria provided in Item #3 above used for identifying beneficiaries eligible for the MTM program.			
6. Applicant will coordinate the MTM program with the Medicare chronic care improvement program (CCIP) under section 1807 of the Social Security Act.			
7. Applicant will provide drug claims data to Chronic Care Improvement Programs (CCIP) for those beneficiaries that are enrolled in CCIPs in a manner specified by CMS.			
Applicant will report to CMS specified data on MTM programs in the manner prescribed by CMS. (See Section 3.11 Reporting Requirements)			
9. Applicant will establish an appropriate policy on how they will set MTM fees to pharmacists or others providing MTM services for covered Part D drugs. The policy will explain how the Applicant's fee or payment structure takes into account the resources used and the time required for by those providing MTM services.			
The Applicant agrees to submit to CMS on April 18, 2005 a description on how they will set MTM fees to pharmacists or others providing MTM services for			

covered Part D drugs. The policy will explain how the Applicant's fee or payment		
structure takes into account the resources used and the time required for by		
those providing MTM services.		

• NOTE: In providing responses to items 5 and 10 above follow these directions: The responses must be submitted to CMS by 5p.m. EST on April 18, 2005. The responses should be submitted to CMS by email in a word document and courier. The emailed response should be sent to <a href="mailto:drugbenefitimpl@cms.hhs.gov">drugbenefitimpl@cms.hhs.gov</a> and the subject line must read Benefit Design Responses. Please include your contract number in the file name as well as in the cover page. The cover page should also specify that the responses are amendments to the March 23, 2005 application that are due on April 18, 2005. The cover page must be signed by an authorized representative, officer, chief executive officer, or general partner of the business organization that is applying for qualification to enter into a Part D contract with CMS. Clearly identify the element—3.2.4A5 or 3.2.4A10—in your response. The responses should be combined with additional responses required in Section 3.2.3. The responses must also be sent by courier to:

Centers for Medicare & Medicaid Services (CMS)

Marietta Mack

Mail Stop S1-05-06/Location S2-04-05

Attn: Benefit Design Responses

7500 Security Boulevard

Baltimore, Maryland 21244-1850

### 3.2.5 Electronic Prescription Program

### A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO THE FOLLOWING QUALIFICATION TO BE  APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'  OR 'NO' TO THE FOLLOWING QUALIFICATION BY PLACING A CHECKMARK IN THE  RELEVANT COLUMN.	YES	NO	Requesting Waiver? Yes or No
Once electronic prescribing standards are published and in effect, the Applicant agrees to have an electronic prescription program that supports electronic prescribing with pharmacies as well as physicians.			

### 3.3 Service Area/Regions

If Applicant is a local MA-PD (as defined under 42 CFR 422.2) then the plan service area does not have to meet a regional definition and therefore is waived as allowed under 42 CFR 423.153 (e). Such Applicant should proceed to Section 3.4 of the application.

## A. Only Applicants that intend to offer a Regional PPO plan must complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN.	YES	NO	Requesting Waiver? Yes or No
IN THE RELEVANT COLUMN.			
Applicant will offer Part D coverage for the entire MA region(s) to be operated under the Regional PPO plan.			

B. Provide as an attachment, the table below, indicating the MA region(s) you plan to serve. MA region may be found at the following website:
<a href="https://www.cms.hhs.gov/medicarereform/mmaregions/pdpmaosum.asp">www.cms.hhs.gov/medicarereform/mmaregions/pdpmaosum.asp</a>. Be sure to list both the MA region name and associated number.

MA Region	MA Region Number

### 3.4 Pharmacy Access

If a MA Private Fee for Service plan [as described in 42 CFR §422.4 (a)(3)] (1) offers qualified prescription drug coverage, and provides plan enrollees with access to covered Part D drugs dispensed at all pharmacies, without regard to whether they are contracted network pharmacies, and (2) does not charge cost-sharing in excess of that required for qualified prescription drug coverage is not required to meet the pharmacy access standards used as the basis for this section (3.4) then as allowed under 42 CFR §423.120 (a)(3)(i), the Applicant should proceed to sub-section 3.5 "Enrollment and Eligibility" of the application.

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARI IN THE RELEVANT COLUMN:		NO	Requesting Waiver? Yes or No
<ol> <li>Applicant agrees to permit in their plan networks any pharmacy that is willing to accept and meets the plans' standard terms and conditions. However, terms and conditions may vary, particularly with respect to payment terms to accommodate geographical areas (e.g. rural pharmacies) or different types of pharmacies (e.g. mail order and retail), provided that all similarly-situated pharmacies are offered the same standard terms and conditions.</li> </ol>	•		
<ol><li>Applicant agrees not to require a pharmacy to accept insurance risk as a condition of participation in the MA-PD's network.</li></ol>			
Applicant's network pharmacy contracts contain provisions governing submitting claims to a real-time claims adjudication system.	ı		
Applicant's network pharmacy contracts contain provisions governing providing access to negotiated prices.			

5.	Applicant's network pharmacy contracts contain provisions regarding charging/		
	applying the correct cost-sharing amount, including that which applies to		
	individuals qualifying for the low-income subsidy.		
6.	Applicant's network pharmacy contracts contain provisions governing informing		
	the Part D enrollee at the point of sale (or at the point of delivery for mail order		
	drugs) the lowest-priced, generically equivalent drug, if one exists for the		
	beneficiary's prescription, as well as any associated differential in price.		

Note: While CMS realizes that contracts with Indian Health Services, Indian Tribes and Tribal organizations and Urban Indian Organization (I/T/U), Federally Qualified Health Centers (FQHC) and Rural Health Centers (RHC) may be counted for purposes of meeting the pharmacy access standards, it should be noted that contracts with these pharmacies may not be used as a substitution for inclusion in plan networks of retail pharmacies.

B. Provide as an attachment the unsigned standard terms and conditions offered in the contract (or addenda to the contract) for each of the following types of pharmacies: Retail, Mail Order, Home Infusion, I/T/U, and Long-Term Care. The mail order contract is only necessary if the plan is offering mail order. If there are several different types of standard terms and conditions for the same type of pharmacy, please provide all versions. For example, if different terms for retail pharmacies apply depending upon geographic location, all standard terms must be provided.

- Contracts (or addenda to contracts) must contain all of the required provisions described in 3.1.1D for contracts or letters of agreement with the Applicant's subcontractors except for the following numbers 1, 3, 5, 6, 7, and 14.
- No signature pages need be submitted at this time, but each Applicant must make a complete file of such pages available for inspection upon CMS' request.

C. Provide electronic lists of the Pharmacy Access Contract Citations demonstrating that the applicable requirements in 3.1.1D, 3.4A. 3.4.5 and 3.4.6B and any other requirements cited in Appendix X are included in such contracts. Submit this data by creating a spreadsheet in Microsoft Excel that mimics Appendix X. Provide this attachment on a CD as instructed in Section 2.5. This information must be clearly labeled to indicate to which party of the joint enterprise the information pertains.

### 3.4.1 Retail Pharmacy

If your organization will provide enrollees with access to covered Part D drugs through pharmacies owned and operated by your organization under 42 CFR §423.120 (a) (3) (i) these pharmacies may be included in determining pharmacy network access for your MA-PD population. Pharmacies owned and operated by your organization may be included in your pharmacy network to demonstrate equivalent access in items A, B, C below.

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN:			
1. Applicant agrees to meet the CMS Standards for Convenient Access [§423.120 (a)(1) and (2)] as early as March 23, 2005 but no later than July 15, 2005 (See Appendix VI).			
2. Applicant agrees that if these pharmacy access standards are not fully met by March 23, 2005, that applicant will resubmit the analysis in Section 3.4.1 (A) on August 1, 2005.			
3. Applicant agrees to permit enrollees to receive benefits which may include a 90-day supply of covered Part D drugs at any of its network pharmacies that are retail pharmacies instead of at a network mail-order pharmacy.			_

Note: Concerning the rural access standard, there may be several States for which the standard will be impossible or impracticable to meet given the lack of infrastructure. CMS will identify these States and make an exception to meeting this requirement based on analysis of the number of retail pharmacies in the State, the State's Medicare population and the access ratios across plans that include these States in their service area.

B. . Using Geographic Information Systems (GIS) or similar software, demonstrate in the March 23, 2005 application, the applicant's pharmacy access ratios for their intended service area, using only the pharmacies for which contracts are executed for the Part D benefit. Please note that:

- As defined in 42 CFR 423.100:
  - urban areas are five-digit ZIP Codes in which the population density is greater than 3,000 persons per square mile;
  - suburban areas are five-digit ZIP Codes in which the population density is equal to or greater than 1,000 persons per square mile and less than or equal to 3,000 persons per square mile; and
  - rural areas are five-digit ZIP Codes in which the population density is less than 1,000 persons per square mile.

Note: If the convenient access standards are not satisfied on the March 23, 2005 application, then these analyses must also be submitted to CMS on August 1, 2005.

- The demonstration of pharmacy access must be based on a computation using of beneficiary counts by Zip Code provided by CMS at <a href="http://www.cms.hhs.gov/pdps">http://www.cms.hhs.gov/pdps</a>
   (File name: "MCareEnrbyZip062004.zip) Due to periodic changes in ZIP codes, CMS recognizes that some ZIP codes in the data provided by CMS may not "map" to current ZIP code listings for your service area. These ZIP codes may be excluded from your summary analyses.
- Maps and tables must be generated for the Applicant's entire service area using the locations for the pharmacy network under contract for the Part D benefits and the standard beneficiary file provided to bidders at <a href="http://www.cms.hhs.gov/pdps/">http://www.cms.hhs.gov/pdps/</a> (Filename: "MCareEnrbyZIP062004.zip"). This network analysis may include only retail (non-mail-order) pharmacies, I/T/U pharmacies, and pharmacies operated by a FQHC or RHC as provided in Section 423.120 (a) (1) and (a) (2). Applicants are responsible for insuring the urban, suburban, and rural definitions used in their

analyses conform with the definitions for these areas as provided in 42 CFR 423.100. Most network access analysis programs default to classifications consistent with the regulatory requirements. Upon request by an applicant, CMS will provide urban, suburban, and rural classifications by beneficiary Zip Code based on the relation of CMS beneficiary ZIP codes to ZIP code Tabulation Areas (ZCTAs). The population densities used in this file are based on the U.S, Census Bureaus ZCTA Gazetteer file. Use of this more detailed file by applicants is not required. This file is available to applicant organizations that require further detail for mapping classification purposes. 2

 Maps and tables generated by the mapping software must include aggregate urban, suburban, and rural ratios for the entire service area to be served by the PDP sponsor, as well as urban, suburban, and rural ratios for each region, state, county, and Zip Code included under the program.

C. Provide an electronic list of all contracted retail pharmacy outlets included in the analysis. Submit this data by creating a spreadsheet in Microsoft Excel that mimics the table below. Provide this attachment on a CD as instructed in Section 2.5. Note: If MA-PD owns pharmacies provide this information. Submit this list to CMS with the March 23, 2005 application and again on August 1, 2005 if there are changes.

Full Name of		Full A	Address		Pharmacy Telephone	Contact	NABP Number	Pharmacy Type Mark Preferred (P) or
Pharmacy					Number			Non-Preferred (N)
	Street	City	State	Zip				

### 3.4.2 Out of Network Pharmacy

### A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN:			
Applicant agrees to ensure that enrollees have adequate access to covered Part D drugs dispensed at out-of-network pharmacies when an enrollees cannot reasonably be expected to obtain such drugs at a network pharmacy and provided such enrollees do not access Part D drugs at an out-of-network pharmacy (or a physician's office) on a routine basis.			
<ol> <li>Applicant agrees to ensure that enrollees have adequate access to covered Part D drugs dispensed at physician offices for covered Part D drugs that are appropriately dispensed and administered in physician offices (e.g. Part D- covered vaccines).</li> </ol>			
3. Applicant agrees to abide by Section 423.124(e) relating to the financial responsibility for out-of-network access to covered Part D drugs and may require its Part D enrollees accessing covered Part D drugs to assume financial responsibility for any differential between the out-of-network pharmacy's usual and customary price and the PDP sponsor plan allowance, consistent with the requirements of § 423.124(d)(2)(i)(B) and § 423.124(e).			
4. Applicant agrees to develop policies and procedures governing reasonable rules			

<sup>&</sup>lt;sup>1</sup> See <a href="http://www.census.gov/geo/www/gazetteer/places2k.html">http://www.census.gov/geo/www/gazetteer/places2k.html</a>

-

<sup>&</sup>lt;sup>2</sup> Requests for this file should be submitted to <a href="mailto:dhodges@cms.hhs.gov">dhodges@cms.hhs.gov</a> with the subject line: ZIP Classification File Request

to appropriately limit out-of-network access and to include at least the following:		
Beneficiary is guaranteed out-of-network access when:		
<ul> <li>Traveling outside his or her plan's service area and runs out of or loses his</li> </ul>		
or her covered Part D drugs or becomes ill and needs a covered Part D		
drug, and cannot access a network pharmacy;		
Not able to obtain a covered Part D drug in a timely manner within his or		
her service area because, for example, there is no network pharmacy		
within a reasonable driving distance that provides 24/7 service;		
Filling a prescription for a covered Part D drug and that particular drug (for		
example, an orphan drug or other specialty pharmaceutical) is not regularly		
stocked at an accessible network retail or mail-order pharmacy;		
<ul> <li>Provided covered Part D drugs dispensed by an out-of-network institution-</li> </ul>		
based pharmacy while a patient is in an emergency department, provider-		
based clinic, outpatient surgery, or other outpatient setting.		

### 3.4.3 Mail Order Pharmacy

### A. Complete the table below:

APPLICANTS MAY OFFER A MAIL ORDER OPTION IN ADDITION TO THEIR			Requesting
CONTRACTED PART D PHARMACY NETWORK BUT MAIL ORDER PHARMACIES DO	YES	NO	Waiver?
NOT COUNT IN MEETING NETWORK ADEQUACY STANDARDS. INDICATE 'YES' OR			Yes or No
'NO' WHETHER SUCH MAIL ORDER PHARMACY IS OFFERED.			
Applicant will offer mail order pharmacy as a part of its Part D plan(s).			

B. Provide an electronic list with the March 23, 2005 application of all Applicant-owned and/or contracted mail order pharmacies to provide Part D benefits – only if your PDP will include them. Submit this data by creating a spreadsheet in Microsoft Excel that mimics the table below. Provide this attachment on a CD as instructed in Section 2.5. Provide an updated list on August 1, 2005 if there are changes.

Full Name		Full A	ddress		Pharmacy	Contact	NABP	Pharmacy Type		
of					Telephone		Number	mber   Mark Preferred (P) or		
Pharmacy	Street	City	State	Zip	Number			Non-Preferred (N)		
-		•		·						

### **3.4.4 Home Infusion Pharmacy**

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN:			
Applicant agrees to provide adequate access to home infusion pharmacies.			
2. Applicant provides the analysis required in "B" below with the March 23 <sup>rd</sup> application, or Applicant agrees to provide it on August 1, 2005.			

3.	Applicant agrees that its network contracts will address Part D drugs delivered in		
	the home setting through home infusion therapy pharmacies.		

**B.** Provide a map and table generated by mapping software of the dispersion of the Applicant's contracted home infusion pharmacies, as well as the ratios of beneficiaries to these pharmacies for the entire service area and for each region, state and county. Use the standard beneficiary file provided to bidders at <a href="http://www.cms.hhs.gov/pdps/">http://www.cms.hhs.gov/pdps/</a> (Filename:

"MCareEnrbyZIP062004.zip"). Based on the findings in this map and table, describe how the home infusion pharmacies in the Applicant's network adequately provides the Part D benefit to the beneficiaries that the Applicant intends to enroll throughout its proposed service area. Submit this information to CMS with the March 23, 2005 application or on August 1, 2005. Note: Documentation for Home Infusion Access (3.4.4 B) and Home Infusion Pharmacy List (3.4.4 C) must be submitted at the same time.

C. Provide an electronic list of all contracted Home Infusion Pharmacies to provide Part D benefits. Submit this data by creating a spreadsheet in Microsoft Excel that mimics the table below. Provide this attachment on a CD as instructed in Section 2.5.

Full Name		Full A	ddress		Pharmacy	Contact	NABP	Pharmacy Type
of Pharmacv	Street	City	State	Zip	Telephone Number		Number	Mark Preferred (P) or Non-Preferred (N)
								710/17/0/0//04 (71)

### 3.4.5 Long -Term Care (LTC) Pharmacy

#### A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN:			
Applicant agrees to offer standard contracting terms and conditions to all long-term care pharmacies in its service area. These terms and conditions must include all the performance and service criteria for long-term care pharmacies that CMS will specify in a future Long-Term Care Guidance document     Applicant agrees to recognize the CMS special election period (SEP) or open enrollment period for institutionalized individuals (OEPI) for Part D drug plan			
enrollment and disenrollment for beneficiaries entering, living in, or leaving a long-term care facility.			
3. Applicant agrees that if contracts with long-term care pharmacies are not fully executed by March 23, 2005, that applicant will need to resubmit the analysis requested below by August 1, 2005.			
<ol> <li>Applicant agrees that it will contract with a sufficient number of LTC pharmacies to provide all of the plan's institutionalized enrollees convenient access to their Part D benefit.</li> </ol>			

Note: CMS will release Long-Term Care Guidance in early March, 2005. This document will contain a list of Performance and Service Criteria, as referenced in item #1 of the above table. Applicants will be required to incorporate, at a minimum, those revised criteria in any LTC pharmacy network contract.

B. Provide a work plan with the March 23, 2005 application outlining the Applicant's strategy for completing contracting with long-term care pharmacies in proposed service area by July 15, 2005 and in time to submit access information by August 1, 2005. The

work plan should include (but is not limited to) activities associated with and target dates for the following major milestones: identification of LTC pharmacies, conducting outreach, contract offering, arrangements for discussion/negotiation, anticipated contract closure, tracking progress and assessing progress to modify approach as necessary.

C. On August 1, 2005 provide an electronic list of all contracted Long-Term Care Pharmacies to provide Part D benefits. Submit this data by creating a spreadsheet in Microsoft Excel that mimics the table below. Provide this attachment on a CD as instructed in Section 2.5.

Full Name		Full Ad	ddress		Pharmacy	Contact	NABP	Pharmacy Type		
of					Telephone Number		Number	Mark Preferred (P)		
Pharmacy	Street	Street City State		Zip				or Non-Preferred		
-				-				(N)		
								·		

D. Describe how the long-term care pharmacies in the Applicant's network represents a sufficient number of long-term care pharmacies to provide all of the plan's institutionalized enrollees with convenient access to their Part D benefit..

# 3.4.6 Indian Health Service, Indian Tribe and Tribal Organization, and Urban Indian Organization (I/T/U) Pharmacy

#### A. Complete the table below:

APPLICANT MUST ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING			Requesting
QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN TO BE	YES	NO	Waiver?
APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT:			Yes or No
Using the list of I/T/U pharmacies provided at <a href="http://www.cms.hhs.gov/pdps">http://www.cms.hhs.gov/pdps</a> or <a href="http://www.cms.hhs.gov/aian/">http://www.cms.hhs.gov/pdps</a> or <a href="http://www.cms.hhs.gov/aian/">http://www.cms.hhs.gov/pdps</a> or <a href="http://www.cms.hhs.gov/pdps">http://www.cms.hhs.gov/pdps</a> or <a href="http://www.cms.hhs.gov/pdps">http://www.cms.hhs.gov/pdps</a> or <a href="http://www.cms.hhs.gov/pdps">http://www.cms.hhs.gov/pdps</a> at least one I/T/U pharmacy.			

NOT ALL MA-PD REGIONS HAVE I/T/U PHARMACIES. IF THE APPLICANT'S SERVICE			Requesting
AREA COVERS ANY REGION THAT INCLUDES I/T/U PHARMACIES, THEN THE	YES	NO	Waiver?
APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Yes or No
BE APPROVED FOR A MA-PD CONTRACT. IF <u>ALL</u> OF THE APPLICANT'S SERVICE			
AREA <u>DOES NOT</u> INCLUDE I/T/U PHARMACIES, THEN THE APPLICANT MAY ANSWER			
'NO' AND STILL BE APPROVED FOR A PDP CONTRACT SINCE THESE REQUIREMENTS			
DO NOT APPLY. ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING			
QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:			
Applicant agrees to offer standard terms and conditions that conform to the model contract addenda provided by CMS to all I/T/U pharmacies in its service area. These model contract addenda are located at: <a href="http://www.cms.hhs.gov/pdps/">http://www.cms.hhs.gov/pdps/</a> and <a href="http://www.cms.hhs.gov/aian/">http://www.cms.hhs.gov/pdps/</a> and <a href="http://www.cms.hhs.gov/aian/">http://www.cms.hhs.gov/aian/</a> . The model contract addenda account for differences in the operations of I/T/U pharmacies and retail pharmacies.			

Note: Information for Part D Sponsors on Contracting with Indian Health Care Providers is located at: http://www.cms.hhs.gov/pdps and http://www.cms.hhs.gov/aian/.

C. Provide below a work plan with the March 23, 2005 application, outlining the Applicant's strategy for completing contracting with I/T/U pharmacies in proposed service area by July 15, 2005 and in time to submit access information on August 1, 2005. Work plan should include (but is not limited to) target dates for these major milestones: Identification of I/T/U pharmacies, conducting outreach, contract offering, arrangements for discussion/negotiation, anticipated contract closure, tracking progress and assessing progress to modify approach as necessary. Also included in this work plan should be a period not to exceed 45 days for an I/T/U pharmacy to enter into a contract with the plan once the contract has been offered to the pharmacy.

D. On August 1, 2005, provide an electronic list (by State) for each I/T/U Pharmacy. Submit this data by creating a spreadsheet in Microsoft Excel that mimics the table below. Provide this attachment on a CD as instructed in Section 2.5.

Full Name of	F	ull A	ddres	s	Phone Number	Contact	NABP or ASEP No.	Pharmac y Type			s of Contract k with an "X"	
Pharmacy	Street	City	State	Zip				Mark Preferred (P) or Non- Preferred (N)	Date of Offer	Accepted	Declined	Under Negotiation

### 3.5 Exceptions, Appeals, and Grievances

A. Exceptions and Appeals - Complete the table below:

ADDITIONS MILES ATTEST (VEC) TO EACH OF THE FOLLOWING OHALIEICATIONS TO BE

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE			Requesting
APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' OR	YES	NO	Waiver?
'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK IN			Yes or No
THE RELEVANT COLUMN.			
Applicant will adopt policies and procedures for beneficiary coverage determination, exceptions, and appeals consistent with 42 CFR §423 subpart M.			
2. Applicant will assure that it will comply with 423.578(a) and 423.578 (b) which require an MA-PD sponsor to grant a tiering or off –formulary exception whenever it determines an exception is medically appropriate because the preferred drug (or on-formulary drug in the case of a formulary exception request): (a) would not be as effective for the enrollee as the requested drug; or (b) would have adverse effects for the enrollee, or (c) both.			
<ol> <li>Applicant will make its enrollees aware of the coverage determination, exceptions, and appeals process through information provided in the Evidence of Coverage and outreach materials.</li> </ol>			
<ul> <li>4. Applicant will establish and maintain a process designed to track and address in a timely manner enrollees' exceptions requests, requests for coverage determination, re-determination, requests for reconsideration by the Independent Review Entity (IRE), and requests for review by the Administrative Law Judge (ALJ) received both orally and in writing, that includes, at a minimum: <ul> <li>Date of receipt;</li> <li>Date of any notification;</li> <li>Disposition of request; and</li> <li>Date of disposition</li> </ul> </li> </ul>			
5. Applicant will make available to CMS upon CMS request, exception and appeals			

-		
records.		l
10001do.		i

### **B.** Grievances - Complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS			Requesting
(AS THEY WOULD APPLY TO THE OPERATION OF YOUR ORGANIZATION'S PART	YES	NO	Waiver?
D BENEFIT) TO BE APPROVED FOR A PART D ADDENDUM TO THE PART C			
CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING			Yes or No
QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN.			
Applicant will establish and maintain a process designed to track and			
address enrollees' grievances and assures that they will adopt appropriate timelines, policies and procedures and train the relevant staff and			
subcontractors on such policies and procedures in accordance with 42CFR			
423.564.			
Applicant Will make enrollees aware of the grievance process through			
information and outreach materials.			
3. Applicant Will accept grievances from enrollees at least by telephone and in			
writing (including facsimile)			
4. Applicant will maintain, and provides upon request by CMS access to			
records on all grievances received both orally and in writing, that includes,			
at a minimum:			
Date of receipt of the grievance			
<ul> <li>Mode of receipt of grievance (i.e. fax, telephone, letter, etc.)</li> </ul>			
<ul> <li>Person or entity that filed the grievance</li> </ul>			
Subject of the grievance			
Final disposition of the grievance			
Date the enrollee was notified of the disposition			

Note: A grievance is any complaint or dispute, other than one that involves a coverage determination, expressing dissatisfaction with any aspect of a MA-PD sponsor's operations, activities, or behavior, regardless of whether remedial action is requested. Examples of subjects of a grievance include, but are not limited to:

- Timeliness, appropriateness, access to, and/or setting of services provided by the MA-PD sponsor
- Concerns about waiting times, demeanor of pharmacy or customer service staff
- A dispute concerning the timeliness of filling a prescription or the accuracy of filling the prescription.

### 3.6 Coordination of Benefits

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN:			
Applicant develops and operates a system for collecting information from enrollees about enrollees' other health insurance, including whether such insurance covers outpatient prescription drugs.			

2.	Applicant will permit SPAPs and other third party payers to coordinate benefits as required by the regulations in Subpart J, Part 423, 42 CFR. For example, an SPAP might pay the premium for supplemental benefits on behalf of a beneficiary.		
3.	Applicant will abide by the guidance of CMS regarding the Coordination of		
	Benefit requirements to be released July 1, 2005.		
4.	Applicant agrees to pay user fees as required under 423.6 and may be required		
	in 423.464 (c ).		
5.	Applicant agrees not to impose fees on SPAPs or other third-party insurers		
	unrelated to the cost of coordination of benefits.		

### 3.7 Tracking Out-of Pocket Costs (TrOOP)

### A. Complete the table below:

AF	PLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE	APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OF	'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN	THE RELEVANT COLUMN:			
1.	Applicant will track each enrollee's true out of pocket (TrOOP) costs reflecting the amount the enrollee has spent out of pocket during a program year on covered Part D drugs.			
2.	Applicant will accept data concerning third party payers in a format to be specified by CMS no later than April for use in the Applicant's TrOOP calculation.			
3.	Applicant will provide each enrollee with a report on their TrOOP status at least monthly.			
4.	Applicant will provide enrollees daily access to their current TrOOP status through the organization's toll-free customer service phone number.			
5.	In the event of disenrollment, Applicant agrees to provide TrOOP status of the beneficiary as of the effective date of the disenrollment.			

### 3.8 Marketing/Beneficiary Communications

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN.	YES	NO	Requesting Waiver? Yes or No
Applicant will make available to beneficiaries only those marketing materials that comply with CMS' marketing guidelines and complies with CMS approval procedures in accordance with CMS guidelines and regulations to be issued in April 2005.			
Annually and at the time of enrollment, the Applicant agrees to provide enrollees information about the following MA-PD features, as described in the marketing guidelines:			

D 51	1	
Benefits;  The second of		
Types of Pharmacies in the Pharmacy Network;		
Out-of-network Pharmacy Access;		
Formulary;		
Premiums;		
Service Area;		
<ul> <li>Quality and Performance Indicators;</li> </ul>		
<ul> <li>Utilization Management Procedures;</li> </ul>		
<ul> <li>Frequency of Beneficiary Grievances and Appeals; and</li> </ul>		
Financial Condition of the PDP Sponsor		
The Applicant further agrees to provide general coverage information, utilization and		
grievance information to any beneficiary upon request.		
3. Applicant will maintain a toll-free customer service call center that is open during		
usual business hours and provides customer telephone service in compliance		
with standard business practices. This means that the Applicant must comply		
with at least the following:		
<ul> <li>Call center operates during normal business hours, but not less than</li> </ul>		
Monday through Friday from 8:00 AM to 4:30 PM for those time zones		
in which the Applicant offers a MA-PD (Drug Card Standard);		
<ul> <li>Eighty percent of all incoming customer calls are answered within 30</li> </ul>		
seconds;		
The abandonment rate of all incoming customer calls does not exceed		
5 percent;		
<ul> <li>Call center provides thorough information about the MA-PD benefit</li> </ul>		
plan, including co-payments, deductibles, and network pharmacies;		
Call center features an explicit process for handling customer		
complaints; and		
Call center shall provide service to non-English speaking and hearing		
impaired beneficiaries		
4. Applicant will operate an Internet Web site that a) provides all the information		
described in Item #2 of this table, b) describes the Applicant's PDPs' current		
formularies, and c) provides 60-days' notice to potential and current plan		
enrollees of the removal or change in the tier placement of any drug on the plan's		
formulary.		
5. Applicant will provide its plan enrollees, in a form understandable to enrollees		
and on at least a monthly basis for those months in which the enrollees use their		
Part D benefits, an explanation of benefits that states a) the item or service for		
which payment was made; b) notice of the enrollee's right to an itemized		
statement; c) a year-to-date statement of the total Part D benefits provided in		
relation to deductibles, coverage limits, and annual out-of-pocket thresholds; d)		
cumulative year-to-date total of incurred costs; and e) applicable formulary		
changes.		

### 3.9 Provider Communications

### A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN THE RELEVANT COLUMN:			
Applicant operates a toll-free call center to respond to inquiries from pharmacies and providers regarding the Applicant's Medicare prescription drug benefit. Inquiries will concern such operational areas as claims processing, benefit coverage, claims submission, and claims payment.			

### 3.10 Compliance Plan

#### A. Complete the table below:

AP	PLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING			Requesting
QL	ALIFICATIONS TO BE APPROVED FOR A PART D ADDENDUM TO THE PART	YES	NO	Waiver? -
C	CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING			Yes or No
QL	ALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:			
1.	Applicant will implement a compliance plan that consists of written policies, procedures, and standards of conduct articulating your organization's commitment to abide by all applicable Federal and State standards.			
2.	Applicant will implement a compliance plan that designates a compliance officer and compliance committee accountable to senior management.			
3.	Applicant will implement a compliance plan that includes effective training and education between the compliance officer, organization employees, contractors, agents, and directors.			
4.	Applicant will implement a compliance plan that includes effective lines of communication between the compliance officer and organization employees, contractors, agents and directors and members of the compliance committee.			
5.	Applicant will implement a compliance plan that includes disciplinary standards that are well-publicized.			
6.	Applicant will implement a compliance plan that includes procedures for internal monitoring and auditing.			
7.	Applicant will implement a compliance plan that includes procedures for ensuring prompt response to detected offenses and development of corrective action initiatives, relating to the Applicant's contract as a Part D sponsor.			
8.	Applicant will implement a compliance plan that includes a comprehensive plan to detect, correct, and prevent fraud, waste and abuse.			

Note: CMS recommends to Applicants that they include in their compliance plans provisions requiring the reporting of fraud and abuse to the appropriate government authority. Part D sponsors that self-report violations will continue to receive the benefits of voluntary self-reporting found in the False Claims Act and Federal sentencing guidelines.

Note: CMS acknowledges that prospective MA-PD sponsors may not have time to develop a satisfactory compliance plan prior to the due date for this application. Therefore, the Applicant must provide brief responses to the following elements as part of its application, which may reflect a finalized compliance plan or a work in progress toward a final plan..

- B. Describe below the fraud and abuse section of your organization's compliance plan as it would apply to the operation of your Medicare prescription drug benefit plan:
- C. Provide a copy of your organization's policies, procedures, and standards of conduct that articulate your organization's commitment to detecting and preventing waste, fraud and abuse among your Part D plans and those with whom you contract. *Provide this attachment on a CD as instructed in Section 2.5.*

- D. Identify below your organization's compliance officer, provide his/her resume, and describe his/her place in your organization (i.e., to whom does he/she directly report?):
- E. Describe below your organization's fraud and abuse training program, including the frequency of such training:
- F. Describe below how standards of conduct and procedures for reporting potential fraud and abuse issues are publicized within your organization:
- G. Describe below your procedures for internal monitoring and auditing to protect the Medicare Trust Fund from waste, fraud and abuse in the Part D program (including frequency and responsible staff):
- H. Describe below the process your staff will follow to identify possible offenses and how these matters would be reported to CMS and/or its contractors:

### 3.11 Reporting Requirements

Α	PPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
В	E APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'	YES	NO	Waiver?
o	R 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK			Yes or No
IN	THE RELEVANT COLUMN:			
	CLAIMS DATA			
1.	The Applicant or the Applicant's representative, such as a third party administrator (TPA), has data management processes and data systems capable of accomplishing collection of data in either an NCPDP or X12 format in a batch mode. Data to be collected will encompass quantity, type, and costs of pharmaceutical prescriptions filled for enrollees. The plan must link this information to Medicare beneficiary identification numbers (HIC#s).			
2.	The Applicant or the Applicant's representative, such as a third party administrator (TPA), has data management processes and data systems capable of accomplishing submission of prescription drug claims information for Medicare enrollees for every Part D drug prescription in the format required by CMS, using batch submission processes. Data to be submitted will encompass quantity, type and costs of pharmaceutical prescriptions filled for enrollees. The plan must link this information to Medicare beneficiary indentification numbers (HIC#s).			
3.	The Applicant or the Applicant's representative, such as a third party administrator (TPA), has data management processes and data systems capable of accomplishing submission of data to CMS via the Medicare Data Communications Network (MDCN) as referenced in Section 2.7.			
	The Applicant or the Applicant's representative, such as a third party administrator (TPA), has data management processes and data systems capable of accomplishing performance of data edit and quality control procedures to ensure accurate and complete prescription drug data.  The Applicant or the Applicant's representative, such as a third party administrator (TPA), has data management processes and data systems			

capable of accomplishing Correction of all data errors identified by CMS.	
6. The Applicant or the Applicant's representative, such as a third party	
administrator (TPA), has data management processes and data systems	
capable of accomplishing collection of data for dates of service within the	
coverage period with a 3-month closeout window for the submission of remaining	
unreported claims data.  7. The Applicant or the Applicant's representative, such as a third party	
administrator (TPA), has data management processes and data systems	
capable of accomplishing provision of additional information for the purposes of	
reconciliation of risk factors, low income subsidy payments, reinsurance	
payments, and risk corridor as required by CMS.	
Applicant will send and receive claims data for third party payers from the CMS	
contractor that will serve as the clearinghouse for all Part D beneficiary	
outpatient drug claims.	
- Company and the Company and	
REBATE DATA	
9. The Applicant or the Applicant's representative has accounting systems capable	
of accomplishing the provision of documentation, as specified by CMS, to	
support the accuracy and completeness of data. Documentation will be provided to CMS in response to an audit based request	
to CMS in response to an audit-based request.  10. The Applicant will report rebate dollars on a quarterly basis at the	
manufacturer/brand name level (unique strength and package size not required)	
in the manner specified by CMS.	
11. The Applicant or the Applicant's representative has accounting systems capable	
of accomplishing the production of financial reports to support rebate accounting.	
The rebate accounting must allow for step-down cost reporting in which rebates	
received at the aggregate level may be apportioned down to the level of plan	
enrollees.	
on ones.	
UTILIZATION MANAGEMENT DATA	
12. The Applicant will report quarterly the generic dispensing rate which is calculated	
as the number of generic drugs dispensed to the patient divided by the total	
number of drugs dispensed within a given time period.	
13. If formulary management tools include prior authorization the Applicant will	
report to CMS on a quarterly basis information about the use of that tool. Such	
information may include, but is not limited to:	
The number of pharmacy transactions denied due to the need for prior authorization	
The number of prior authorizations requested	
· · ·	
The number of prior authorizations approved	
EXCEPTIONS AND APPEALS	
14. The Applicant will report at a frequency specified by CMS the following	
information related to exceptions and appeals that may include, but is not limited	
to:	
# Step edits attempted	
# Step edits failed	
• # Appeals	
# Appeals overturned	
MEDICATION THERAPY MANAGEMENT DATA	
15. The Applicant will report semi-annually (by dates to be published by CMS each	
year) information related to the implementation of its Medication Therapy	
Management program that may include, but is not limited to:	
# Beneficiaries targeted	
# Beneficiaries participating	
# Beneficiaries declined	
Total drug cost for patients in MTM on a per enrolled MTM beneficiary	
	<del></del>

per month basis		
OTHER DATA		
16. The Applicant will provide CMS with routine administrative reports (pursuant to 42 CFR 423.514 (a)) on a variety of measures that concern the Applicant's performance in the administration of the Part D benefit. Such reports shall be submitted according to instruction issued with timely notice by CMS.		
SUPPORTING <u>WWW.MEDICARE.GOV</u>		
17. The Applicant will submit pricing and pharmacy network information to be publicly reported on <a href="www.medicare.gov">www.medicare.gov</a> in order to provide Medicare beneficiaries with necessary information regarding prescription drug costs under the respective plans. Details regarding this data requirement will be posted on <a href="www.cms.hhs.gov">www.cms.hhs.gov</a> by April 20, 2005.		
CONFLICT OF INTEREST		
18. The Applicant will provide financial and organizational conflict of interest reports to CMS, pursuant to instructions to be issued by CMS.		

Note: Further detail on our approach to monitoring and oversight, including the exact reporting measures will be posted on the CMS website not later than April 2005. Price Compare requirements will be posted in May 2005.

### 3.12 Data Exchange Between MA-PD and CMS

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:	YES	NO	Requesting Waiver? Yes or No
HPMS			
<ol> <li>Applicant will use HPMS to communicate with CMS in support of the application process, formulary submission process, bid submission process, ongoing operations of the Part D program, and reporting and oversight activities. PDPs are required to secure access to HPMS in order to carry out these functions.</li> </ol>			
ENROLLMENT & PAYMENT			
Applicant will reconcile PDP data to CMS enrollment/payment reports within 45 days of availability.			

Applicant will submit enrollment/payment attestation forms within 45 days of CMS report availability.	
---	--

### **3.13 Claims Processing**

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO			Requesting
DE ADDROVED FOR A DART D ADDENDUM TO THE DART C CONTRACT. ATTEST (VES)			Waiver?
BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES'			Yes or No
OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK	YES	NO	70007110
IN THE RELEVANT COLUMN:			
Applicant develops and operates an on-line claims processing system that			
operates in real time to ensure accurate and timely payment of all claims			
submitted by network pharmacies on behalf of Part D plan enrollees. System operates according to the following standards:			
98% response within 4 seconds			
99% of all claims paid with no errors			
99% system availability			
Note: In preparation for implementation CMS (except for scheduled down time and disasters)			
will conduct testing and otherwise monitor for the impact of TrOOP system interfaces with plan			
claims processing systems, and adjust these standards as appropriate if necessary.			
2. Applicant develops and operates a paper claims processing system designed to			
pay claims submitted by non-network pharmacies on behalf of Part D plan			
enrollees. Applicant processes claims according to the following standards:			
100% of claims requiring no intervention handled within 15 calendar			
days			
100% of claims requiring intervention handled within 30 calendar days			
99% of all manually keyed claims paid with no errors			
3. If mail order pharmacy is offered, Applicant mail order processing meets three			
business day turnaround time from the point of receipt of prescription for in-stock			
<ul><li>items with no intervention to the point of shipment.</li><li>4. If mail order pharmacy is offered, Applicant mail order processing meets five</li></ul>			
business day turnaround time from the point of receipt of prescription for in-stock			
items with intervention to the point of shipment.			
Applicant will develop and have available for CMS inspection a complete			
description of your claims adjudication system including:			
Hardware and software			
Operating system			
MediSpan or First Data Bank database, including number of iterations			
saved			
Number of sites processing claims (including disaster recovery back-up)			
systems)			
<ul> <li>System volume in covered lives, including the number of transactions</li> </ul>			
the system can support per day and per hour			
6. Applicant will develop and have available to CMS upon request policies and			
procedures that include a complete description and flow chart detailing the			
claims adjudication process for each:			
Contracted network pharmacies  Out of water and all a processing.			
Out-of-network pharmacies			
Paper claims  Patch processed plains			
Batch-processed claims     Manual claim entry (a.g. for processing direct member raimburgement)			
Manual claim entry (e.g. for processing direct member reimbursement)  7. Applicant will develop and have excitable to CMS upon request religion and			
7. Applicant will develop and have available to CMS upon request policies and			
procedures that include a complete description of claim detail management, including:			
The length of time that detailed claim information is maintained online			
The length of time that detailed claim information is maintained offline	1	1	

(not less than 12 months)	
The data storage process after it is no longer online	
The length of time that detailed claim information is stored when it is no	
longer online (not less than 10 years)	
Applicant will develop and have available to CMS upon request policies and	+ + + + + + + + + + + + + + + + + + + +
procedures that include a complete description of the accessibility of this	
information for data capture purposes and flow chart of the claims data retrieval process for each:	
Entire claims history file	
Encounter data required by state mandates	
Encounter data required by alternate funding sources	
Out-of-pocket maximum/deductible files	
9. Applicant will develop and have available to CMS upon request policies and	
procedures that include a description of how overpayments and underpayments	
to pharmacies, as well as to enrollees, are handled and recovery procedures.	
10. Applicant will develop and have available to CMS upon request policies and	
procedures that include a complete description of procedures surrounding	
disputed claims, including:	
The steps that a pharmacy and/or an enrollee must follow to dispute a	
claim reimbursement	
The average amount of time needed to resolve a claims dispute	
Turnaround time standards for dispute resolution.	
11. Applicant will have a robust testing process that will identify and correct any plan	
configuration errors prior to implementation.	
12. Applicant will accept eligibility files and any prior claims data electronically in	
NCPDP format.	
13. Applicant can and will document the manner and extent to which it has tested	
benefit designs such as drug exclusions or quantity limitations and plan	
parameters such as co-payments or benefit maximums.	

### 3.14 Privacy

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE			Requesting
APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' OR	YES	NO	Waiver?
'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK IN THE			Yes or No
RELEVANT COLUMN:			
Applicant agrees not to use the Social Security Number (SSN) or Medicare ID Number on the enrollees' identification cards.			
2. Applicant will notify each beneficiary, prior to enrollment or at the time of enrollment, of expected uses and disclosures of the beneficiary's protected health information, as well as the beneficiary's rights and Applicant's duties with respect to such information. Such notice is to be provided in plain language containing sufficient detail to advise the beneficiary of the uses and disclosures permitted or required under applicable law.			
3. Applicant will obtain written authorization for all uses and disclosures of protected health information not otherwise permitted under the HIPAA Privacy Rule.  Beneficiaries may authorize disclosure of their protected health information to a third party, such as their employer.			

4.	Applicant will ensure that all its agents and subcontractors comply with all the requirements of 45 CFR Parts 162 and 164 when performing functions on the Applicant's behalf.		
5.	Applicant will comply with the requirements applicable to covered entities in 45 CFR Part 160 relating to use of national identifiers.		
6.	Applicant will comply with any applicable standards, implementation specifications, and requirements in the Standards for Electronic Transactions under 45 CFR Parts 160 and 162 subparts I <i>et seq</i> .		

### 3.15 Security and Record Retention

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A PART D ADDENDUM TO THE PART C CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:	YES	NO	Requesting Waiver? Yes or No
SECURITY			
1. Applicant attests that at least one of the following conditions is true: a) By completing the HIPAA Security Attestation Statement, (Appendix V), as of the initial enrollment date, appropriate administrative, technical, and physical safeguards will be in place to protect the privacy of protected health information in accordance with 45 CFR §164.530(c), and that Applicant will meet the standards, requirements, and implementation specifications as set forth in 45 CFR part 164, subpart C, the HIPAA Security Rule, prior to beginning enrollment of beneficiaries; or b) If Applicant is unable to provide this attestation, Applicant provides a plan for coming into compliance with the specifications as set forth in the Security Rule as requested in 3.16B below. Applicant is encouraged, but not required, to use the Information Security Program references as provided by the National Institute of Standards and Technology (NIST) found at <a href="https://www.nist.gov">www.nist.gov</a> in describing your efforts to implement reasonable security measures.			
RECORD RETENTION			
2. The Applicant will maintain, for 10 years, books, records, documents, and other evidence of accounting procedures and practices consistent with 42 CFR §423.505(d).			

#### 4.0 CERTIFICATION

I, the undersigned, certify to the following:

- I have read the contents of the completed application and the information contained herein is true, correct, and complete. If I become aware that any information in this application is not true, correct, or complete, I agree to notify the Centers for Medicare & Medicaid Services (CMS) immediately and in writing.
- 2) I authorize CMS to verify the information contained herein. I agree to notify CMS in writing of any changes that may jeopardize my ability to meet the qualifications stated in this application prior to such change or within 30 days of the effective date of such change. I understand that such a change may result in termination of the approval.
- 3) I agree that if my organization meets the minimum qualifications and is Medicareapproved, and my organization enters into a Part D contract with CMS, I will abide by the requirements contained in Section 3.0 of this Application and provide the services outlined in my application.
- 4) I agree that CMS may inspect any and all information necessary including inspecting of the premises of the Applicant's organization or plan to ensure compliance with stated Federal requirements including specific provisions for which I have attested. I further agree to immediately notify CMS if despite these attestations I become aware of circumstances which preclude full compliance by January 1, 2006 with the requirement stated here in this application as well as in Part 423 of 42 CFR of the regulation.
- 5) I understand that in accordance with 18 U.S.C. § 1001, any omission, misrepresentation or falsification of any information contained in this application or contained in any communication supplying information to CMS to complete or clarify this application may be punishable by criminal, civil, or other administrative actions including revocation of approval, fines, and/or imprisonment under Federal law.

6)	I further certify that I am an authorized representative, officer, chief executive
	officer, or general partner of the business organization that is applying for
	qualification to enter into a Part D addendum to my organization's Medicare
	Advantage contract with CMS.

Authorized Representative Name (printed)	Title
Authorized Representative Signature	Date (MM/DD/YYYY)

### **5.0 APPENDICES**

**Subject: Notice of Intent to Apply** 

#### APPENDIX I

#### **Notice of Intent to Apply**

#### Complete this form to indicate your intent to apply. Applicant Organization's Legal Entity Name: Applicant Organization's Corporate Address (Street, City, State, Zip - No Post Office Boxes): Type of Medicare Prescription Drug Benefit Contract Request: ☐ PDP If PDP Sponsor, Type of Risk Anticipated: Full Risk ☐ Partial Risk Both If MA-PD, type of product represented by this notice. Note: Select only one and provide a different notice for each product ☐ HMO POS □ PFFS ΠPSO ☐ Regional PPO PROVIDE THE INFORMATION BELOW REGARDING YOUR PHARMACY BENEFITS Pharmacy Benefit Management Organization's Full Name. Note: If Applicant contracts with multiple Pharmacy Benefit Management Organizations, be sure to list all: Does the Applicant anticipate submitting a formulary? Note: CMS is using this information to understand how many formularies it may need to review beginning April 18, 2005. ☐ Yes ☐ No If yes, indicate how many formularies you anticipate to submit: If no, indicate if all drugs will have the same cost-sharing: ☐ Yes □ No PROVIDE THE INFORMATION BELOW FOR THE PERSON WHO WILL ACT AS THE MAIN CONTACT Name of Individual: Title: Address of Individual: (Street, City, State, Zip - No Post Office Boxes): Direct Telephone Number: Fax Number: Email Address: IDENTIFY THE REGION APPLICANT INTENDS TO SERVE: Note: MA & PDP region number information may be found at the following website: www.cms.hhs.gov/medicarereform/mmaregions/pdpmaosum.asp If PDP Sponsor, identify PDP regions to be served If MA-PD Sponsor offering regional PPO, identify MA regions to using region numbers: be served using region numbers: If MA-PD Sponsor offering local plan, identify state, county, and zip code: PROVIDE THE INFORMATION BELOW ON LICENSURE Are you licensed (or is your application pending at the state) to be a risk-bearing entity in any state in which you propose to offer Part D drug benefits? Yes No If yes, please complete the table below. Add additional rows as necessary. Dates of License List State(s) in which Status of License you Already Possess Complete either Effective and Expiration Dates or Indicate the status using an "X" to or Have Applied for Submission Date mark the appropriate column

License Application

Submitted

Effective

Date

Expiration

Date

Submission

Date

License

Licensed

PROVIDE THE INFORMATION BELOW ON STATE LICENSURE REQUIREMENT WAIVERS. ADD ADDITIONAL			
ROWS AS NECESSARY.			
	Status of	License Requirement Waiver	
List the State(s) for Which	Use the key below to indicate your response.		
a Licensure Requirement	X = Waiver application is to be submitted. Provide anticipated date of submission.		
Waiver has Been or will be	A = Waiver application submitted and approved. Provide date approved.		
Requested	P = Waiver application submitted and pending. Provide date submitted.		
	D = Waiver application denied. Provide date denied.		
	Status Date		

Note: This Notice of Intent to Apply must be emailed to <a href="mailto:drugbenefitimpl@cms.hhs.gov">drugbenefitimpl@cms.hhs.gov</a> by 5:00 p.m. EST on February 18, 2005. Be sure to indicate "NOTICE OF INTENT" in the subject line.

Return Form to: <a href="MDCN@CMS.HHS.GOV">MDCN@CMS.HHS.GOV</a>
Subject: CMS Connectivity Request Form

### APPENDIX II

# CMS CONNECTIVITY REQUEST FORM Prescription Drug Plan

THE FOLLOWING ORGANIZATION IS REQUESTING CONNI	ECTIVITY TO CMS FOR THE PRESCRIPTION DRUG		
Name of Organization:			
Primary Contact Name:	Primary Contact Telephone Number:		
Address (Street, City, State, Zip):			
Telecommunications Contact Name:			
Telecommunications Contact Email:			
Physical Site Address (Must be the physical location for the T1	installation):		
Does your site have leased line IP connectivity into the MDC (AT&T Global Network Services)?	N (Medicare Data Communications Network) via AGNS		
☐ Yes. Please answer questions 2-13. ☐ No. Plea	se answer questions 4-13.		
2. What are the AGNS account names; i.e. BXKY, BXSC, CWF drug card transactions? (For example, the AGNS account for the			
Are there other locations networked to the physical site?			
☐ Yes ☐ No			
If yes please list the city and state below.			
4. What are the IP networks/sub-network masks that will be communicating with CMS? (This is required for both ends of the connectivity so routing can be put in place over the new PVC built across the AGNS.) Please note you may need to contact your network administrator for this information NOTE: If the AGNS router is placed on a ring/segment upstream from the origination network(s), CMS will need to know what the next hop will be out of the AGNS router to get to the cascaded network(s).			
5. Do you currently have Connect: Direct that you will use for t system infrastructure?	he Medicare Prescription Drug Program within your		
☐ Yes. Please answer question a below. ☐ No. Please a	inswer questions b and c below.		
a. Which version of Connect: Direct to you currently have within PC) or satellite (LAN/Server based)?	your infrastructure; i.e. enterprise, workstation (runs on		
b. Please provide the following information for Connect: Direct s infrastructure.	software installation on the hardware resident within your		
Make & Model of Hardware Where Software Will Reside: Number of Processors Associated with this Hardware: Operating System Used on the Hardware:			
c. Who is the contact person(s) who will be responsible for the (Name: Phone Number:	Connect: Direct Software?		
Email Address:			

6. For T1 installation, what type of LAN will connect to the CMS router; i.e. ethernet, token ring?
7. Will this new site require non-portable registered IP addresses from AGNS?  Yes No.
If yes, how many?
If no, what addresses will be used at this site (sub-network/mask) and what IP address/sub-network mask should be used as the LAN interface address on the AGNS router?
8. What protocols will need to be enabled for this site; i.e. IP, SNA?
9. Will this site require the use of a dynamic routing protocol to advertise/learn routes to/from the AT&T Business Services network; i.e. IGRP, EIGRP, OSPF, BGP?
☐ Yes ☐ No
If no, CMS will assume static routes should be used on the router placed at the new site.
10. What IP network(s) or host(s) at this site, including sub-network mask(s), will need to be able to communicate with what IP network(s) or host(s) at other sites and vice versa? Please include subnetwork masks for the destination network(s) as well NOTE: If the AGNS router is placed on a ring/segment upstream from the origination network(s), CMS will need to know what the next hop will be out of the AGNS router to get to the cascaded network(s).
11. Does this site have connectivity out to the Internet?
12. If there is connectivity out to the Internet, please describe the firewall used at the site for which this is applicable.
Socks or proxy: Firewall software/hardware:
13. Is there any unsolicited inbound traffic permitted from the Internet through the firewall?
14. Will AGNS MDCN WAN be connected to the secure side of the firewall?
15. Are there any dial-up connectivity requirements to the sub-network(s) at this site?

Questions about completing the CMS Connectivity Request form should be sent to: <a href="mailto:MDCN@CMS.HHS.GOV">MDCN@CMS.HHS.GOV</a> with Part D Benefit as the subject line.

#### APPENDIX III

### Instructions for Accessing CMS Systems Health Plan Management System (HPMS)

MA-PDs will be required to use HPMS to carry out various CMS Part D functions, including the application process, formulary submission process, bid submission process, ongoing operations of the Part D program, and reporting and oversight activities. MA-PDs will need the following to access HPMS:

- (1) Internet or Medicare Data Communications Network (MDCN) connectivity,
- (2) Use of a Microsoft Internet Explorer web browser (version 5.1 or higher) with 128-bit encryption, and
- (3) A CMS-issued user ID and password with access rights to HPMS for <u>each</u> user within the PDP organization who will require such access.

Applicants should access the CMS website at <a href="http://www.cms.hhs.gov/mdcn/access.pdf">http://www.cms.hhs.gov/mdcn/access.pdf</a> to obtain the latest version of the *Application for Access to CMS Computer Systems* form. In addition to completing each section of the form, as appropriate, the MA-PD user should: 1) check "Mgd Care Org/Group Health Plan" in Section 2 and write HPMS on the first blank line in Section 3a. Once a pending contract number has been assigned, the MA-PD user should include the contract number in Section 2h.

In order to expedite the processing of this request, CMS strongly recommends that organizations refrain from requesting any additional systems access other than HPMS on this particular form submission at this time. You <u>must</u> also sign and date page 2 containing the Privacy Act statement and return it along with the form. Your request cannot be processed without this signature and date. The original signed form (both pages) must be mailed to the following address:

Centers for Medicare & Medicaid Services Attention: Marietta Mack Mail Stop S1-05-06 / Location S2-04-05 7500 Security Boulevard Baltimore, Maryland 21244-1850

Please contact Don Freeburger (410-786-4586 or <u>DFreeburger@cms.hhs.gov</u>) or Greg Buglio (410-786-6562 or <u>GBuglio@cms.hhs.gov</u>) with any questions. CMS will provide you with additional technical instructions on accessing HPMS, including its website address, once your user ID has been processed.

#### **Important Note for Current HPMS Users**

If you a transisitioning MA organization, you do not need to request new CMS user IDs unless you need to obtain HPMS access for new MA-PD users at your organization. Unless otherwise directed by CMS, you will retain your current contract number(s).

If you are a new MA applicant, but your organization already has HPMS access for other CMS functions, such as under another MA product or as a Drug Card Sponsor, you do <u>not</u> need to request new CMS User IDs, unless you need to do so to obtain HPMS access for new MA-PD users at your organization. Once your receive your new pending MA contract number, you will be directed to provide CMS with the list of current User IDs that require access to the new MA contract number in HPMS. CMS will provide all organizations with those instructions at the time of contract enumeration.

#### Other CMS Systems

Applicants will also be required to obtain access to other CMS systems in order to perform necessary operational functions, including, but not limited to, enrollment and claims submission. Instructions for obtaining access to those other systems will be provided to Applicants separately.

### **APPENDIX IV**

### **Banking Information Form**

As Government vendors, organizations with Medicare contracts are paid by the Department of Treasury through an Electronic Funds Transfer (EFT) program. Government vendor payments are directly deposited into corporate accounts at financial institutions on the expected payment date. Additionally, CMS must have the EIN/TIN and associated name as registered with the IRS.

Please provide the following information to assist the Centers for Medicare and Medicaid Services in establishing payment arrangements for your organization.

### **ORGANIZATION INFORMATION**

Name of Organization:			DBA, if any:	
Full Address of Organization	on (Street, City, Zip):			
Contact Person Name:			Telephone Number:	
Contract Numbers, if know	vn:			
Employer/Tax Identification	n Number (EIN/TIN):			
EIN/TIN Name (Name of E A W-9 may be required	Business for tax purposes as	registered with	the IRS):	
Full Address for 1099 Tax	Form (Street, City, Zip):			
FINANCIAL INSTITUT	ION			
Name of Bank:				
Full Address of Bank (Stre	eet, City, Zip):			
ACH/EFT Coordinator Nar	ne:		Telephone Number:	
Nine Digit Routing Transit	(ABA Number):	L		
Depositor Account Title:				
Depositor Account Number	er:			
Check Account Type: (Ple	ease Attach a Copy of A Void	ded Check)		
Checking	Savings			
	OF ORGANIZATION'S A	UTHORIZED	REPRESENTATIVE	
Date:	<u> </u>			
Title:				
Print Name:				
Phone Number:				

### APPENDIX V

# Summary of Medicare Part D Regulatory Requirements Waived for Medicare Advantage Prescription Drug (MA-PD) Applicants

Part D Regulation	Regulatory Requirement(s)	Basis and Rationale for Waiver
	Description	
42 CFR 423Subpart I, excepting 42 CFR 423.440 (which concerns Federal preemption of State law and prohibition of	Licensure and Solvency – Applicant must be licensed to bear risk in the State in which it intends to operate or apply for a licensure waiver and meet CMS solvency standards.	Duplicative of MA Organization requirements for licensure and solvency under 42 CFR 422.6 (i); 42 CFR 422.400; and 42 CFR 422.501).
State premium taxes) 42 CFR 423.153(b) &(d) Waiver applies to MA-PFFS only	Utilization Management - Applicant must have a cost effective utilization management system.	Waiver stated in regulations at 42 CFR §423.153 (e) excuses MA PFFS organizations from meeting the utilization management requirements specified in 423.153 (b) .
42 CFR 423.153(b) &(d) Waiver applies to MA-PFFS only	Medication Therapy Management Program – Applicant must have a program to manage medication therapy to optimize outcomes, reduce adverse drug interactions.	Waiver stated in regulations at 42 CFR §423.153 (e) excuses MA PFFS organizations from meeting Medication Therapy Management Program requirements specified in 42 CFR §423.155.
42 CFR 423.112 (a)	Service Area – Applicant must offer a Part D plan that serves at least an entire PDP regions.	Conflicts with MA regulations (42 CFR 422.2) that allow MA organizations to offer local MA plans (i.e., plans that serve less than an entire state).
42 CFR 423.120 (a)(7)(i) Waiver applies only to MA-PDs that operate their own pharmacies	Pharmacy Network – Applicant must offer its Part D plan benefit through a contracted retail pharmacy network that meets CMS convenient access standards.	Waiver stated in regulations at 42 CFR 423.120(a)(7) (i) excuses from the CMS convenient access standards those MA organizations that administer their Part D benefit through pharmacies owned by the MA organization if that organization's pharmacy network access is comparable to the CMS convenient access standards . {Note: Applicants will be expected to provide comparable information in the application for organizational pharmacies}
42 CFR 423.120(a)(7)(ii) Waiver applies to MA-PFFS plan that provides access through all pharmacies.	Pharmacy Network – Applicant must offer its Part D plan benefit through a contracted retail pharmacy network that meets CMS convenient access standards	Waiver stated in regulations at 42 CFR §423.120 (a) (7) (ii). excuses from the CMS convenient access standards those MA-PFFS organizations that offer a qualified prescription drug coverage, and provide plan enrollees with access to covered Part D drugs dispensed at all pharmacies, without regard to whether they are contracted network pharmacies and without charging cost-sharing in excess of the requirements for qualified prescription drug coverage. {Note: Applicants are not required to provide information on contracted pharmacies or access information}
	Enrollment and Eligibility – Applicant	Duplicative of MA requirements under 42

Part D Regulation	Regulatory Requirement(s)  Description	Basis and Rationale for Waiver
42CFR 423.34 42 CFR 423.36 42 CFR 423.38 42 CFR 423.42 42 CFR 423.44	agrees to accept Part D plan enrollments and determine Part D plan eligibility consistent with Part D program requirements.	CFR 422 Subpart B - Eligibility, Election, and Enrollment. MA organizations will conduct enrollment and determine eligibility consistent with MA program requirements. These requirements mirror those stated in the Part D regulation
42 CFR 423.514(b) and (c)	Reporting Requirements – Applicant must report information concerning significant business transactions.	Duplicative of MA requirements for reporting significant transactions under 42 CFR 422.500 and 42 CFR 422.516(b) and (c) and requirements for providing annual financial statements.
42 CFR 423.514(e)	Reporting Requirements – Applicant must notify CMS of any loans or any other special arrangements it makes with contractors, subcontractors, and related entities.	Duplicative of MA requirement for reporting loans or special arrangements under 42 CFR 422.516(e).

#### APPENDIX VI

#### **Pharmacy Access Standards**

§ 423.120 Access to Covered Part D Drugs

### (a) Assuring pharmacy access.

- (1) Standards for convenient access to network pharmacies. Except as provided in paragraph (a) (7) of this section, a Part D plan must have a contracted pharmacy network, consisting of retail pharmacies sufficient to ensure that for beneficiaries residing in each State in the prescription drug plan's service area, (as defined in § 423.112 (a)), each State in a regional MA-PD plan's service area, (as defined in § 422.2 and § 422.455 (a) of this chapter), a local MA-PD plan's service area (as defined in § 422.2 of this chapter), or a cost plan's geographic area (as defined in § 417.401 of this chapter), the following requirements are satisfied:
  - (i) At least 90 percent of Medicare beneficiaries, on average, in urban areas served by the Part D plan live within 2 miles of a network pharmacy that is a retail pharmacy or a pharmacy described under paragraph (a) (2) of this section;
  - (ii) At least 90 percent of Medicare beneficiaries, on average, in suburban areas served by the Part D plan live within 5 miles of a network pharmacy that is a retail pharmacy or a pharmacy described under paragraph (a) (2) of this section; and
  - (iii) At least 70 percent of Medicare beneficiaries, on average, in rural areas served by the Part D plan live within 15 miles of a network pharmacy that is a retail pharmacy or a pharmacy described under paragraph (a) (2) of this section.
- (2) Applicability of some non-retail pharmacies to standards for convenient access. Part D plans may count I/T/U pharmacies and pharmacies operated by Federally Qualified Health Centers and Rural Health Centers toward the standards for convenient access to network pharmacies in paragraph (a) (1) of this section.

### APPENDIX VII

# CERTIFICATION OF MONTHLY ENROLLMENT AND PAYMENT DATA RELATING TO CMS PAYMENT TO A MA-PD

Pursuant to the contract(s) between the Centers for Medicare and Medicaid Services (CMS), and
Drug Plan" governing the operation of the following MA-PDs
(plan identification numbers), the MA-PD hereby requests payment under the contract, and in doing so, makes the following certifications concerning CMS payments to the MA-PD. The MA-PD acknowledges that the information described below directly affects the calculation of CMS payments to the MA-PD and that misrepresentations to CMS about the accuracy of such information may result in Federal civil action and/or criminal prosecution. This certification shall not be considered a waiver of the MA-PD's right to seek payment adjustments from CMS based on information or data that does not become available until after the date the MA-PD submits this certification.
1. The MA-PD has reported to CMS for applications received in the month of (month and year) all new enrollments, disenrollments, and changes in Plan Benefit Packages with respect to the above-stated MA-PDs. Based on best knowledge, information, and belief, all information submitted to CMS in this report is accurate, complete, and truthful.
2. The MA-PD has reviewed the CMS monthly membership report and reply listing for the month of (month and year) for the above-stated MA-PDs and has submitted requests to the IntegriGuard, under separate cover, for retroactive adjustments to correct payment data when the MA-PD has more accurate information. This may include enrollment status and State and County Code related to specific beneficiary. For those portions of the monthly membership report and the reply listing to which the MA-PD raises no objection, the MA-PD, through the certifying CEO/CFO will be deemed to have attested, based on best knowledge, information, and belief, to their accuracy, completeness, and truthfulness.
NAME:
TITLE: (MA-PD)
(WITTE)

NOTE: The person signing this form must be the CEO, CFO, or an individual delegated the authority to sign on behalf of on of the CEO or CFO and who reports to the CEO or CFO. Otherwise the certification will be considered invalid, per CFR 423.505 (k).

#### APPENDIX VIII

## CERTIFICATION THAT SUBCONTRACTORS MEET THE REQUIREMENTS OF SECTION 3.1.1D

A. I, the undersigned, certify, on behalf of LEGAL NAME, to the following:

The contracts submitted as attachments to Section 3.1.1:

- 1. Clearly identify the parties to the contract (or letter of agreement);
- 2. Describe the functions to be performed by the subcontractor, as well as any reporting requirements the subcontractor has to the Applicant identified in Section 3.1.1B of the application;
- 3. Contain language clearly indicating that the subcontractor has agreed to participate in your Medicare Prescription Drug Benefit program (except for a network pharmacy if the existing contract would allow participation in this program), and flow-down clauses requiring their activities be consistent and comply with the Applicant's contractual obligations as a PDP sponsor;
- 4. Contain language describing the services to be performed in a manner that encompasses the services required to support the Medicare Prescription Drug Benefit program;
- 5. Describe the payment the subcontractor will receive for performance under the contract, if applicable;
- 6. Are for a term of at least the first year of the program (i.e., January 1, 2006 through December 31, 2006);
- 7. Are signed by a representative of each party with legal authority to bind the entity;
- 8. Contain language obligating the subcontractor to abide by all applicable Federal and State laws and regulations and CMS instructions;
- 9. Contain language obligating the subcontractor to abide by State and Federal privacy and security requirements, including the confidentiality and security provisions stated in the regulations for the program at 42 CFR §423.136;
- 10. Contain language ensuring that the subcontractor will make their books and other records available in accordance with 42 CFR §423.505(i)(2), which generally states these regulations give HHS, the Comptroller General, or their designees the right to inspect, evaluate and audit books and other records and that these rights continue for a period of 10 years from the final date of the contract period or the date of audit completion, whichever is later;
- 11. Contain language stating that the subcontractor will ensure that beneficiaries are not held liable for fees that are the responsibility of the Applicant;
- 12. Contain language stating that if the Applicant, upon becoming a Part D sponsor, delegates an activity or responsibility to the subcontractor, that such activity or responsibility may be revoked if CMS or the Part D sponsor determines the subcontractor has not performed satisfactorily. The subcontract may include remedies in lieu of revocation to address this requirement;
- 13. Contain language specifying that the Applicant, upon becoming a Part D sponsor, will monitor the performance of the subcontractor on an ongoing basis; and
- 14. Contain language that the Part D sponsor retains the right to approve, suspend, or terminate any arrangement with a pharmacy if the subcontractor will establish the pharmacy network or select pharmacies to be included in the network.
- B. I certify that I am authorized to sign on behalf of the Applicant.
- C. I understand that CMS will review the submitted contracts to ensure that they comply with the contracting requirements stated in Section 3.1.1D of the Solicitation for Applications from Prescription Drug Plans (PDPs)/Medicare Advantage Prescription Drug Plan Sponsors/Cost Plan Sponsors. When a submitted contract does not meet a requirement, CMS will ask the Applicant to resubmit the contract in question. I understand the Applicant's failure to provide in a timely manner fully executed contracts that meet CMS requirements may affect CMS'

2005.	liment into its Part D plan(s) on November
Authorized Representative Name (printed)	Title
Authorized Representative Signature	Date (MM/DD/YYYY

### Appendix IX Citations of Section 3.1.1D Requirements in Subcontracts submitted as attachments to Section 3.1.1D

**INSTRUCTIONS:** Applicants must complete the following chart for each subcontractor submitted under Section 3.1.1D.

Applicants must identify where in each contract the following elements may be found.

Section	Requirement	Citation
3.1.1D1	The parties to the contract	Ottation
3.1.1D2	The functions to be performed by the subcontractor, as well as any reporting requirements the subcontractor has to the Applicant identified in Section 3.1.1B of the application.	
3.1.1D3	Language clearly indicating that the subcontractor has agreed to participate in your Medicare Prescription Drug Benefit program (except for a network pharmacy if the existing contract would allow participation in this program), and flow-down clause.	
3.1.1D4	Language describing the services to be performed in a manner that encompasses the services required to support the Medicare Prescription Drug Benefit program.	
3.1.1D5	The payment the subcontractor will receive for performance under the contract, if applicable.	
3.1.1D6	Are for a term of at least the first year of the program.	
3.1.1D7	Are signed by a representative of each party with legal authority to bind the entity.	
3.1.1D8	Language obligating the subcontractor to abide by all applicable Federal and State laws and regulations and CMS instructions.	
3.1.1D9	Language obligating the subcontractor to abide by State and Federal privacy and security requirements, including the confidentiality and security provisions stated in the regulations for the program at 42 CFR §423.136.	
3.1.1D10	Language ensuring that the subcontractor will make their books and other records available in accordance with 42 CFR §423.505(i)(2), which generally states these regulations give HHS, the Comptroller General, or their designees the right to inspect.	
3.1.1D11	Language stating that the subcontractor will ensure that beneficiaries are not held liable for fees that are the responsibility of the Applicant.	
3.1.1D12	Language stating that if the Applicant, upon becoming a Part D sponsor, delegates an activity or responsibility to the subcontractor, that such activity or responsibility may be revoked if CMS or the Part D sponsor determines the subcontractor has not performed satisfactorily. The subcontract may include remedies in lieu of revocation to address this requirement.	
3.1.1D13	Language specifying that the Applicant, upon becoming a Part D sponsor, will monitor the performance of the subcontractor on an ongoing basis.	

3.1.1D14	, , ,	
	approve, suspend, or terminate any arrangement with a	
	pharmacy if the subcontractor will establish the pharmacy	
	network or select pharmacies to be included in the	
	network.	

## APPENDIX X Citations for Pharmacy Access Contracts

INSTRUCTIONS: Applicants must complete the following chart (which contains applicable Section 3.1.1 D) requirements AND additional requirements specific to Pharmacy Access, Long-Term Care and I/T/U contracts) for each pharmacy contract submitted under Section 3.4. Applicants must identify where in each contract the following elements reside.  Indicate the type of pharmacy to which contract applies:		
	☐ Mail Order ☐ Home Infusion ☐ Long-Term Care ☐ I (for tribal contracting)	I/T/U (for IHS contracting)
to which t	sions listed below must be in all pharmacy contracts. If one the pharmacy must abide, provide the relevant documents tation accordingly.	
Section	Requirement	Citation
2 / / 2 2		
3.1.1D2	The functions to be performed by the subcontractor, as well as any reporting requirements the subcontractor has to the Applicant identified in Section 3.1.1B of the application.	
3.1.1D4	Language describing the services to be performed in a manner that encompasses the services required to support the Medicare Prescription Drug Benefit program.	
3.1.1D8	Language obligating the subcontractor to abide by all applicable Federal and State laws and regulations and CMS instructions.	
3.1.1D9	Language obligating the subcontractor to abide by State and Federal privacy and security requirements, including the confidentiality and security provisions stated in the regulations for the program at 42 CFR §423.136.	
3.1.1D10	Language ensuring that the subcontractor will make their books and other records available in accordance with 42 CFR §423.505(i)(2), which generally states these regulations give HHS, the Comptroller General, or their designees the right to inspect.	
3.1.1D11	Language stating that the subcontractor will ensure that beneficiaries are not held liable for fees that are the responsibility of the Applicant.	
3.1.1D12	Language stating that if the Applicant, upon becoming a Part D sponsor, delegates an activity or responsibility to the subcontractor, that such activity or responsibility may be revoked if CMS or the Part D sponsor determines the subcontractor has not performed satisfactorily. The subcontract may include remedies in lieu of revocation to address this requirement.	
3.1.1D13	Language specifying that the Applicant, upon becoming a Part D sponsor, will monitor the performance of the subcontractor on an ongoing basis.	
3.4A3	Provisions governing submitting claims to a real-time claims adjudication system.	
	Note: Applicant may indicate for I/T/U pharmacies and for certain pharmacies that are allowed to submit claims in the	

	X12 format that these may be batch processed.	
3.4A4	Provisions governing providing access to negotiated prices.	
3.4A5	Provisions regarding charging/applying the correct cost- sharing amount, including that which applies to individuals qualifying for the low-income subsidy.	
3.4A6	Provisions governing informing the Part D enrollee at the point of sale (or at the point of delivery for mail order drugs) of the lowest-priced, generically equivalent drug, if one exists for the beneficiary's prescription, as well as any associated differential in price.	

### **Elements Specific to Long-Term Care Contracts**

Note: CMS will release Long-Term Care Guidance in early March 2005. This document will contain an updated list of performance and service criteria as referenced in Item #1 of 3.4.5A. Applicants will be required to incorporate at a minimum, these criteria in any LTC pharmacy network contract. Applicant must list the criteria below, and then identify where the element is met in the contract.

Performance/Service Criteria Citation

Elements Specific to Indian Health Service, Indian Tribe and Tribal Organization, and Urban Indian Organization

(I/T/U) Pharmacy Contracts

Note: Sections referenced are the provisions listed in the model I/T/U and HIS Addenda, located at <a href="http://www.cms.hhs.gov/pdps/">http://www.cms.hhs.gov/pdps/</a> and <a href="http://www.cms.hhs.gov/aian/">http://www.cms.hhs.gov/aian/</a>. The I/T/U Contracts must contain language consistent with the model tribal pharmacy and IHS addenda that address the following:

Item 3	Description of the provider.	
Item 4	Counting of costs paid for by provider toward any deductibles.	
Item 5	Persons eligible for services of the provider.	
Item 6	The applicability of certain Federal law.	
Item 7	The non-taxable status of the provider (only in contracts with tribal pharmacies)	
Item 8	Insurance and indemnification.	
Item 9	Applicability of state licensing law to provider's employees.	
Item 10 (I/TU only)	Provider eligibility for payments (only in contracts with tribal pharmacies).	
Item 11 (I/T/U) & Item 10 (IHS)	Dispute resolution.	
Item 12 (I/T/U) & Item 11 (IHS)	Federal law as the governing law.	
Item 13 (I/T/U) & Item 12 (IHS)	The contract will apply to all pharmacies and dispensaries operated by the provider.	

Item 14 (I/T/U) & Item 13 (IHS)	The contract will not affect the provider's acquisition of pharmaceuticals.
Item 15 (I/T/U) & Item 14 (IHS)	The provider's point of sale processing capabilities.
Item 16 (I/T/U) & Item 15 (IHS)	Claims processing.
Item 17 (I/T/U) & Item 16 (IHS)	Reasonable and appropriate payment rates.
Item 18 (I/T/U) & Item 17 (IHS)	Any information, outreach or enrollment materials prepared by the Applicant will be supplied at no cost to the provider.
Item 19 (I/T/U) & Item 18 (IHS)	The provider determines the hours of service for the pharmacies or dispensaries of the provider.
Item 19 (IHS only)	The contract will not be an official or implied endorsement by IHS or IHS employees (applicable only to IHS contract).